propranolol has been researched along with Hematochezia in 326 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Hematochezia: The passage of bright red blood from the rectum. The blood may or may not be mixed with formed stool in the form of blood, blood clots, bloody stool or diarrhea.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to compare the recurrence of esophageal varices (EVs) after endoscopic band ligation (EBL) associated with propranolol (PP) versus EBL alone." | 9.20 | Propranolol associated with endoscopic band ligation reduces recurrence of esophageal varices for primary prophylaxis of variceal bleeding: a randomized-controlled trial. ( Bonilha, DQ; Correia, LM; de Paulo, GA; Della Libera, E; Ferrari, AP; Lenz, L; Rodrigues, RA, 2015) |
| "To compare the effects of propranolol (PR) to that of PR plus isosorbide-5-mononitrate (ISMN) on variceal pressure in patients with schistosomiasis." | 9.17 | Effects of propranolol or propranolol plus isosorbide-5-mononitrate on variceal pressure in schistosomiasis. ( Chen, C; Hao, JH; Kong, DR; Li, P; Ma, C; Wang, JG; Wang, M; Xu, JM; Zhang, L, 2013) |
| "In a multicenter, prospective trial, 62 patients with cirrhosis with high-risk esophageal varices were randomized to propranolol (titrated to reducing resting pulse by > or =25%) or banding (performed monthly until varices were eradicated) and were followed up on the same schedule for a mean duration of 15 months." | 9.11 | Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices. ( Gornbein, J; Han, SH; Jensen, DM; Jutabha, R; Martin, P; Savides, T, 2005) |
| "To assess the efficacy of Ligustrazine in combination with propranolol in the prevention of recurrent esophageal varices bleeding following liver cirrhosis, and its act mechanism." | 9.09 | [A randomized controlled study of ligustrazine in combination with propranolol for prevention of recurrent esophageal varices bleeding]. ( Chen, D; Li, X; Zou, J, 2000) |
| "The effect of spironolactone on esophageal variceal pressure (VP) in patients without ascites was investigated." | 9.08 | The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites. ( Fevery, J; Lijnen, P; Nevens, F; VanBilloen, H, 1996) |
| " In the present, double-blind, 24-month, prospective study of patients with endoscopically-proven varices and ultrasonographically-confirmed hepatic fibrosis, the effects of propranolol 160 mg LA and placebo on the incidence of rebleeding and mortality were compared in 82 patients with portal hypertension secondary to schistosomiasis." | 9.07 | Propranolol reduces mortality in patients with portal hypertension secondary to schistosomiasis. ( el Amin, AA; el Tourabi, H; Harron, DW; Homeida, M; Shaheen, M; Woda, SA, 1994) |
| "To compare the efficacy of oral propranolol and sclerotherapy in the prevention of first hemorrhage from esophageal varices, 65 cirrhotic patients with moderate to large esophageal varices and no history of bleeding were included in the prospective controlled trial." | 9.07 | [Propranolol for prophylaxis of first hemorrhage in cirrhotic patients with esophageal varices--a controlled study comparing with sclerotherapy]. ( Kanazawa, H; Kobayashi, M; Kuroda, H; Matsusaka, S; Nakatsuka, K; Nomura, T; Saitoh, H; Tada, N; Watari, A; Yoshizawa, M, 1993) |
| "We conducted a prospective, multicenter, randomized trial to compare the efficacy of sclerotherapy plus propranolol with that of propranolol alone in the prevention of recurrent gastroesophageal bleeding in severely cirrhotic patients." | 9.07 | Does elective sclerotherapy improve the efficacy of long-term propranolol for prevention of recurrent bleeding in patients with severe cirrhosis? A prospective multicenter, randomized trial. ( Anciaux, ML; Ink, O; Labadie, H; Lenoir, C; Marill, JL; Martin, T; Masliah, C; Perrin, D; Poynard, T; Reville, M, 1992) |
| "The objective of this randomized multicenter trial was to assess the prophylactic effect on the incidence and severity of the first variceal hemorrhage of endoscopic sclerotherapy, propranolol and the combination of the two compared with none of these treatments in patients with cirrhosis and esophageal varices." | 9.07 | Prophylaxis of first hemorrhage from esophageal varices by sclerotherapy, propranolol or both in cirrhotic patients: a randomized multicenter trial. The PROVA Study Group. ( , 1991) |
| "Forty-one patients admitted with first episode of bleeding from esophageal varices were enrolled in a trial of the efficacy of oral propranolol to prevent rebleeding during the course of endoscopic sclerotherapy until obliteration." | 9.06 | Evaluation of propranolol for prevention of recurrent bleeding from esophageal varices between sclerotherapy sessions. ( Leth, R; Lind, T; Lönroth, H; Lundell, L; Olbe, L; Sjövall, M, 1990) |
| "In 29 patients admitted with their first bleeding episode from oesophageal varices the varices were obliterated within 6 months by treatment with serial endoscopic sclerotherapy and propranolol or with sclerotherapy only." | 9.06 | Propranolol may prevent recurrence of oesophageal varices after obliteration by endoscopic sclerotherapy. ( Jensen, LS; Krarup, N, 1990) |
| "Among the various treatments of ruptured oesophageal varices two seem to be effective: oral propranolol therapy and ligation of the oesophagus on clip." | 9.06 | [Prevention of recurrent hemorrhage caused by the rupture of esophageal varices in cirrhotic patients. A controlled study of propranolol and clip ligation of the esophagus]. ( Ampelas, M; Aubin, JP; Bauret, P; Bories, P; Daures, JP; Feneyrou, B; Guiry, P; Michel, H; Parelon, G; Prioton, JB, 1989) |
| "Thirty-one patients admitted with the first bleeding episode from oesophageal varices were randomized in a double-blind manner to receive oral propranolol, 160 mg daily, for 6 months (n = 15) or matching placebo (n = 16) for the same period." | 9.06 | Propranolol in prevention of rebleeding from oesophageal varices during the course of endoscopic sclerotherapy. ( Jensen, LS; Krarup, N, 1989) |
| "A prospective, randomised, multicentre, single-blind comparison of propranolol with placebo in the primary prevention of upper gastrointestinal haemorrhage was conducted in 230 cirrhotic patients with large oesophageal varices." | 9.06 | Propranolol in the primary prevention of upper gastrointestinal tract haemorrhage in patients with cirrhosis of the liver and oesophageal varices. ( Calès, P; Pascal, JP, 1989) |
| "To assess the beneficial and harmful effects of carvedilol compared with traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices." | 8.98 | Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. ( Bendtsen, F; Gluud, LL; Hobolth, L; Jeyaraj, R; Morgan, MY; Zacharias, AP, 2018) |
| "To assess the effects of propranolol as compared with placebo on gastrointestinal hemorrhage and total mortality in cirrhotic patients by using meta analysis of 20 published randomized clinical trials." | 8.82 | Meta analysis of propranolol effects on gastrointestinal hemorrhage in cirrhotic patients. ( Cheng, JW; Gu, MJ; Song, ZM; Zhu, L, 2003) |
| "There is no dose-dependent effect of 80-120 mg/day of propranolol on the hemodynamic response in cirrhotic patients with gastroesophageal varices." | 7.91 | Dose-dependent effect of propranolol on the hemodynamic response in cirrhotic patients with gastroesophageal varices. ( Chen, M; He, Q; Wang, Y; Xiao, J; Xu, H; Yin, X; Zhang, F; Zhang, M; Zhang, W; Zhuge, Y; Zou, X, 2019) |
| "A 52-year-old woman with primary biliary cirrhosis who had never had hepatic coma developed it while taking propranolol." | 7.67 | Does propranolol precipitate hepatic encephalopathy? ( Wiesner, RH, 1986) |
| "We determined the clearance of antipyrine before, and during, the administration of propranolol in eight male patients with alcoholic cirrhosis and a recent episode of gastrointestinal bleeding." | 7.66 | Propranolol does not further decrease the clearance of antipyrine in patients with alcoholic cirrhosis. ( Bercoff, E; Larrey, D; Lebrec, D; Pessayre, D, 1983) |
| "Sclerosing peritonitis developed in a 56-year-old white man who had been receiving propranolol (320 mg/day) for hypertension and angina pectoris since December 1976." | 7.66 | Sclerosing peritonitis and propranolol. ( Ahmad, S, 1981) |
| "Propranolol has been used as prophylaxis for variceal bleeding in patients with cirrhosis." | 6.82 | A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis. ( Baik, SK; Jang, JY; Jeong, SW; Kim, DJ; Kim, MY; Kim, SG; Kim, TY; Kim, YS; Lee, B; Seo, YS; Sohn, JH; Suk, KT; Um, SH, 2016) |
| "The cause of recurrent bleeding was esophageal varices in nine patients and esophageal ulcers in five patients." | 6.37 | [Sclerotherapy of esophageal varices using ethanol in combination with propranolol: clinical study of 30 patients]. ( Aubert, A; Chaput, JC; Lemman, M; Naveau, S; Poynard, T, 1988) |
| "Propranolol is a non-selective beta-blocker used as secondary prophylaxis for UVB, but no previous studies have addressed carvedilol effects in rebleeding prevention." | 5.72 | Carvedilol as secondary prophylaxis for variceal bleeding in hepatosplenic schistosomiasis. ( Cançado, GGL; Cardoso, JB; Couto, CA; de Abreu, ES; Faria, LC; Ferrari, TCA; Lima, AMC; Nardelli, MJ; Osório, FMF, 2022) |
| " First-line therapies include carvedilol or propranolol to prevent variceal bleeding, lactulose for hepatic encephalopathy, combination aldosterone antagonists and loop diuretics for ascites, and terlipressin for hepatorenal syndrome." | 5.41 | Diagnosis and Management of Cirrhosis and Its Complications: A Review. ( Parikh, ND; Tapper, EB, 2023) |
| "100) rebled from esophageal varices within a mean time of 8." | 5.27 | [Propranolol prevention of hemorrhagic recurrence caused by rupture of esophageal varices: worsened prognosis in ascites and jaundice]. ( Attali, P; Buffet, C; Etienne, JP; Ink, O; Pelletier, G; Servent, L, 1985) |
| "The aim of this study was to compare the recurrence of esophageal varices (EVs) after endoscopic band ligation (EBL) associated with propranolol (PP) versus EBL alone." | 5.20 | Propranolol associated with endoscopic band ligation reduces recurrence of esophageal varices for primary prophylaxis of variceal bleeding: a randomized-controlled trial. ( Bonilha, DQ; Correia, LM; de Paulo, GA; Della Libera, E; Ferrari, AP; Lenz, L; Rodrigues, RA, 2015) |
| "To compare the effects of propranolol (PR) to that of PR plus isosorbide-5-mononitrate (ISMN) on variceal pressure in patients with schistosomiasis." | 5.17 | Effects of propranolol or propranolol plus isosorbide-5-mononitrate on variceal pressure in schistosomiasis. ( Chen, C; Hao, JH; Kong, DR; Li, P; Ma, C; Wang, JG; Wang, M; Xu, JM; Zhang, L, 2013) |
| "Patients with oesophageal varices undergoing measurement of HVPG before and under propranolol treatment (80-160 mg/day) were included." | 5.17 | Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. ( Ferlitsch, A; Heinisch, BB; Kramer, L; Payer, BA; Peck-Radosavljevic, M; Pinter, M; Reiberger, T; Schwabl, P; Trauner, M; Ulbrich, G, 2013) |
| "We chose 168 patients with cirrhosis and esophageal varices in our hospital and allocated them to EVL and propranolol groups." | 5.16 | [Comparison of endoscopic band ligation and propranolol for the primary prophylaxis of variceal bleeding in cirrhosis]. ( Feng, C; Huang, F; Liu, X; Nie, W; Ren, S, 2012) |
| "Prophylaxis EVL is as effective and as safe as treatment with propranolol in decreasing the incidence of first variceal bleeding and death in cirrhotic patients with high-risk esophageal varices." | 5.12 | Endoscopic variceal ligation versus propranolol in prophylaxis of first variceal bleeding in patients with cirrhosis. ( Chen, CB; Lai, YL; Lay, CS; Lee, FY; Peng, CY; Tsai, YT; Yu, CJ, 2006) |
| "Twenty-five Japanese cirrhotic patients with endoscopically proven, likely to bleed esophageal varices were randomly assigned for propranolol administration (12 patients; group A) and EIS (13 patients; group B) to prevent first esophageal variceal bleeding." | 5.11 | Propranolol alone may not be acceptable to prevent first esophageal variceal bleeding in Japanese cirrhotic patients: randomized controlled trial. ( Akahoshi, T; Hashizume, M; Okita, K; Shimabukuro, R; Sugimachi, K; Tomikawa, M; Tsutsumi, N, 2004) |
| "In a multicenter, prospective trial, 62 patients with cirrhosis with high-risk esophageal varices were randomized to propranolol (titrated to reducing resting pulse by > or =25%) or banding (performed monthly until varices were eradicated) and were followed up on the same schedule for a mean duration of 15 months." | 5.11 | Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices. ( Gornbein, J; Han, SH; Jensen, DM; Jutabha, R; Martin, P; Savides, T, 2005) |
| " This prospective randomized controlled trial compared EVL with drug therapy (propranolol + ISMN) in the prevention of rebleeds from esophageal varices in cirrhotic and noncirrhotic portal hypertension (NCPH) patients." | 5.11 | Evaluation of endoscopic variceal ligation (EVL) versus propanolol plus isosorbide mononitrate/nadolol (ISMN) in the prevention of variceal rebleeding: comparison of cirrhotic and noncirrhotic patients. ( Gupta, R; Sarin, SK; Shahi, H; Wadhawan, M, 2005) |
| "Sixty patients with cirrhosis and oesophageal varices with no history but at high risk of bleeding were randomized to ligation treatment (30 patients) or propranolol (30 patients)." | 5.11 | Endoscopic variceal ligation vs. propranolol for prevention of first variceal bleeding: a randomized controlled trial. ( Elefsiniotis, I; Galanis, P; Goulas, S; Liatsos, C; Mavrogiannis, C; Papanikolaou, IS; Psilopoulos, D; Sparos, L, 2005) |
| " The aim of our study was to find out if propranolol can prevent the bleeding from esophageal varices and if it acts by reducing the portal inflow due to splanchnic vasodilatation." | 5.10 | Long term effects of propranolol on portal pressure in cirrhotic patients. ( Orban-Schiopu, AM; Popescu, CR, 2003) |
| "To compare the effectiveness of lanreotide SR, a new depot formulation injected once-weekly, and propranolol in reducing circadian portal blood flow (PVF) and meal-stimulated hepatic venous pressure gradient (HVPG) in patients with liver cirrhosis." | 5.10 | Effect of propranolol and depot lanreotide SR on postprandial and circadian portal haemodynamics in cirrhosis. ( Koch, L; Layer, G; Sauerbruch, T; Schiedermaier, P; Stoffel-Wagner, B, 2003) |
| "We compared propranolol therapy and endoscopic ligation for the primary prevention of bleeding from esophageal varices." | 5.09 | Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. ( Kumar, M; Lamba, GS; Misra, A; Murthy, NS; Sarin, SK, 1999) |
| "Thirty cirrhotic patients with PHT, grade III to IV oesophageal varices, hepatic venous pressure gradient > or = 12 mmHg and no prior history of upper gastrointestinal bleeding were randomized to receive propranolol (to reduce their pulse rate by 25% from baseline, n = 15) and EVL (weekly to fortnightly until variceal eradication, n = 15)." | 5.09 | Endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleed: preliminary report of a randomized controlled trial. ( Biswas, PK; Das, T; De, BK; Ghoshal, UC; Santra, A, 1999) |
| "To assess the efficacy of Ligustrazine in combination with propranolol in the prevention of recurrent esophageal varices bleeding following liver cirrhosis, and its act mechanism." | 5.09 | [A randomized controlled study of ligustrazine in combination with propranolol for prevention of recurrent esophageal varices bleeding]. ( Chen, D; Li, X; Zou, J, 2000) |
| "Band ligation of esophageal varices may accentuate gastropathy, which in this study was partly relieved by propranolol." | 5.09 | The effects of endoscopic variceal ligation and propranolol on portal hypertensive gastropathy: a prospective, controlled trial. ( Chen, TA; Cheng, JS; Chiang, HT; Hsu, PI; Lai, KH; Lin, CK; Lo, GH; Wang, EM, 2001) |
| "The absence of any effects on the parameters of portal haemodynamics would appear to deny clonidine any significant role in preventing first bleeding resulting from the rupture of oesophageal varices." | 5.08 | Effects of propranolol compared with clonidine on portal haemodynamics: a double-blind cross-over study using duplex-Doppler ultrasonography. ( Cioni, G; Cristani, A; D'Alimonte, P; Romagnoli, R; Tincani, E; Turrini, F; Ventura, E, 1995) |
| "The effect of spironolactone on esophageal variceal pressure (VP) in patients without ascites was investigated." | 5.08 | The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites. ( Fevery, J; Lijnen, P; Nevens, F; VanBilloen, H, 1996) |
| "To compare endoscopic sclerotherapy, propranolol and distal splenorenal shunt in the prevention of rebleeding esophageal varices and mortality in alcoholic cirrhotics." | 5.08 | Prevention of recurrent esophageal bleeding and survival in patients with alcoholic cirrhosis: a randomized study. ( Castro, F; Marquez, E; Medina, R; Molina, A; Oharriz, J; Rubio, CE; Torres, EA; Urbistondo, M, 1996) |
| " In the present, double-blind, 24-month, prospective study of patients with endoscopically-proven varices and ultrasonographically-confirmed hepatic fibrosis, the effects of propranolol 160 mg LA and placebo on the incidence of rebleeding and mortality were compared in 82 patients with portal hypertension secondary to schistosomiasis." | 5.07 | Propranolol reduces mortality in patients with portal hypertension secondary to schistosomiasis. ( el Amin, AA; el Tourabi, H; Harron, DW; Homeida, M; Shaheen, M; Woda, SA, 1994) |
| "Propranolol has been shown to be effective in both primary and secondary treatment of variceal haemorrhage; most primary prevention trials have only included patients with large oesophageal varices." | 5.07 | Effect of propranolol on prevention of first variceal bleed and survival in patients with chronic liver disease. ( Bouchier, IA; Davies, JM; Elliot, R; Hayes, PC; Hislop, WS; Mills, PR; Plevris, JN, 1994) |
| "To compare the efficacy of oral propranolol and sclerotherapy in the prevention of first hemorrhage from esophageal varices, 65 cirrhotic patients with moderate to large esophageal varices and no history of bleeding were included in the prospective controlled trial." | 5.07 | [Propranolol for prophylaxis of first hemorrhage in cirrhotic patients with esophageal varices--a controlled study comparing with sclerotherapy]. ( Kanazawa, H; Kobayashi, M; Kuroda, H; Matsusaka, S; Nakatsuka, K; Nomura, T; Saitoh, H; Tada, N; Watari, A; Yoshizawa, M, 1993) |
| "We conducted a prospective, multicenter, randomized trial to compare the efficacy of sclerotherapy plus propranolol with that of propranolol alone in the prevention of recurrent gastroesophageal bleeding in severely cirrhotic patients." | 5.07 | Does elective sclerotherapy improve the efficacy of long-term propranolol for prevention of recurrent bleeding in patients with severe cirrhosis? A prospective multicenter, randomized trial. ( Anciaux, ML; Ink, O; Labadie, H; Lenoir, C; Marill, JL; Martin, T; Masliah, C; Perrin, D; Poynard, T; Reville, M, 1992) |
| "The objective of this randomized multicenter trial was to assess the prophylactic effect on the incidence and severity of the first variceal hemorrhage of endoscopic sclerotherapy, propranolol and the combination of the two compared with none of these treatments in patients with cirrhosis and esophageal varices." | 5.07 | Prophylaxis of first hemorrhage from esophageal varices by sclerotherapy, propranolol or both in cirrhotic patients: a randomized multicenter trial. The PROVA Study Group. ( , 1991) |
| "In a double-blind randomized trial, the hemodynamic events following the administration of propranolol (n = 51) or a placebo (n = 51) were prospectively studied in cirrhotic patients with esophageal varices." | 5.06 | Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. ( Alberts, J; Bermann, M; Bosch, J; Conn, HO; Fischer, R; Garcia-Tsao, G; Grace, ND; Groszmann, RJ; Navasa, M; Rodes, J, 1990) |
| "Propranolol and endoscopic sclerosis of esophageal varices are the two approaches currently used in prophylaxis of the first gastrointestinal hemorrhage in the cirrhotic patient." | 5.06 | Preventive therapy of first gastrointestinal bleeding in patients with cirrhosis: results of a controlled trial comparing propranolol, endoscopic sclerotherapy and placebo. ( Andreani, T; Balkau, BJ; Beaugrand, M; Grange, JD; Peigney, N; Poupon, R; Poupon, RE; Trinchet, JC, 1990) |
| "Forty-one patients admitted with first episode of bleeding from esophageal varices were enrolled in a trial of the efficacy of oral propranolol to prevent rebleeding during the course of endoscopic sclerotherapy until obliteration." | 5.06 | Evaluation of propranolol for prevention of recurrent bleeding from esophageal varices between sclerotherapy sessions. ( Leth, R; Lind, T; Lönroth, H; Lundell, L; Olbe, L; Sjövall, M, 1990) |
| "In 29 patients admitted with their first bleeding episode from oesophageal varices the varices were obliterated within 6 months by treatment with serial endoscopic sclerotherapy and propranolol or with sclerotherapy only." | 5.06 | Propranolol may prevent recurrence of oesophageal varices after obliteration by endoscopic sclerotherapy. ( Jensen, LS; Krarup, N, 1990) |
| "Among the various treatments of ruptured oesophageal varices two seem to be effective: oral propranolol therapy and ligation of the oesophagus on clip." | 5.06 | [Prevention of recurrent hemorrhage caused by the rupture of esophageal varices in cirrhotic patients. A controlled study of propranolol and clip ligation of the esophagus]. ( Ampelas, M; Aubin, JP; Bauret, P; Bories, P; Daures, JP; Feneyrou, B; Guiry, P; Michel, H; Parelon, G; Prioton, JB, 1989) |
| "Thirty-one patients admitted with the first bleeding episode from oesophageal varices were randomized in a double-blind manner to receive oral propranolol, 160 mg daily, for 6 months (n = 15) or matching placebo (n = 16) for the same period." | 5.06 | Propranolol in prevention of rebleeding from oesophageal varices during the course of endoscopic sclerotherapy. ( Jensen, LS; Krarup, N, 1989) |
| "A prospective, randomised, multicentre, single-blind comparison of propranolol with placebo in the primary prevention of upper gastrointestinal haemorrhage was conducted in 230 cirrhotic patients with large oesophageal varices." | 5.06 | Propranolol in the primary prevention of upper gastrointestinal tract haemorrhage in patients with cirrhosis of the liver and oesophageal varices. ( Calès, P; Pascal, JP, 1989) |
| "To assess the beneficial and harmful effects of carvedilol compared with traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices." | 4.98 | Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. ( Bendtsen, F; Gluud, LL; Hobolth, L; Jeyaraj, R; Morgan, MY; Zacharias, AP, 2018) |
| "To assess the effects of propranolol as compared with placebo on gastrointestinal hemorrhage and total mortality in cirrhotic patients by using meta analysis of 20 published randomized clinical trials." | 4.82 | Meta analysis of propranolol effects on gastrointestinal hemorrhage in cirrhotic patients. ( Cheng, JW; Gu, MJ; Song, ZM; Zhu, L, 2003) |
| "There is no dose-dependent effect of 80-120 mg/day of propranolol on the hemodynamic response in cirrhotic patients with gastroesophageal varices." | 3.91 | Dose-dependent effect of propranolol on the hemodynamic response in cirrhotic patients with gastroesophageal varices. ( Chen, M; He, Q; Wang, Y; Xiao, J; Xu, H; Yin, X; Zhang, F; Zhang, M; Zhang, W; Zhuge, Y; Zou, X, 2019) |
| "EVL plus propranolol is more effective than propranolol alone in the prevention of the first variceal bleeding in patients with liver cirrhosis." | 3.80 | The comparison of esophageal variceal ligation plus propranolol versus propranolol alone for the primary prophylaxis of esophageal variceal bleeding. ( Choi, MS; Gwak, GY; Je, D; Koh, KC; Lee, JH; Paik, SW; Paik, YH; Yoo, BC, 2014) |
| "Propranolol treatment has been used to prevent variceal bleeding; however, controlled trials of its effectiveness have produced conflicting results." | 3.76 | Drug therapy for portal hypertension. ( Rector, WG, 1986) |
| "propranolol, has been shown to be effective in compensated patients with alcoholic cirrhosis." | 3.75 | [Pharmacological therapy of portal hypertension]. ( Miotti, T; Reichen, J, 1985) |
| " In 30 patients with liver cirrhosis at high risk for variceal bleeding, duplex Doppler sonographic parameters (maximal portal flow velocity, portal blood flow, and congestion index) were measured before and 4 h after the administration of 40 mg of propranolol." | 3.70 | Prevention of a first episode of variceal bleeding: role of duplex Doppler sonographic measurement of the acute response to beta-blockers. ( Baraldi, E; Boldrini, E; Cioni, G; Cristani, A; D'Alimonte, P; Pedrazzini, PG; Tincani, E; Turrini, F; Ventura, E; Ventura, P, 1999) |
| "Propranolol can reduce portal hypertension, therefore is recommended in prevention of variceal bleeding in patients with liver cirrhosis." | 3.69 | [Per-rectal scintigraphy of the portal system with pertechnetate TC-99M: effect of propranolol on portosystemic collateral circulation in patients with cirrhosis. Part II]. ( Bołdys, H; Hartleb, M; Nowak, A; Nowak, S; Rudzki, K, 1994) |
| "This study evaluates systemic and splanchnic haemodynamics and the effect of propranolol in 15 patients with presinusoidal portal hypertension (portal vein obstruction, n = 11; schistosomiasis, n = 4)." | 3.67 | Hyperkinetic circulatory syndrome in patients with presinusoidal portal hypertension. Effect of propranolol. ( Braillon, A; Hadengue, A; Lebrec, D; Moreau, R; Roulot, D; Sayegh, R, 1989) |
| "The effectiveness of oral propranolol and sclerotherapy in preventing recurrent bleeding after an endoscopically proven haemorrhage from oesophageal varices was compared in Pugh's grade B and C patients divided into two successive therapeutic groups." | 3.67 | [Prevention of hemorrhagic recurrence in cirrhotic patients. Is sclerotherapy better than propranolol?]. ( Attali, P; Buffet, C; Etienne, JP; Fritsch, J; Honein, K; Ink, O; Pelletier, G, 1988) |
| "A 52-year-old woman with primary biliary cirrhosis who had never had hepatic coma developed it while taking propranolol." | 3.67 | Does propranolol precipitate hepatic encephalopathy? ( Wiesner, RH, 1986) |
| "We determined the clearance of antipyrine before, and during, the administration of propranolol in eight male patients with alcoholic cirrhosis and a recent episode of gastrointestinal bleeding." | 3.66 | Propranolol does not further decrease the clearance of antipyrine in patients with alcoholic cirrhosis. ( Bercoff, E; Larrey, D; Lebrec, D; Pessayre, D, 1983) |
| "Sclerosing peritonitis developed in a 56-year-old white man who had been receiving propranolol (320 mg/day) for hypertension and angina pectoris since December 1976." | 3.66 | Sclerosing peritonitis and propranolol. ( Ahmad, S, 1981) |
| " The aim of this study was to evaluate the effects of 5-MTHF in combination with propranolol on HVPG and nitric oxide bioavailability markers in patients with cirrhosis and portal hypertension." | 3.30 | 5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial. ( Andreone, P; Berzigotti, A; Bosch, J; Di Donato, R; Gitto, S; Renzulli, M; Roncarati, G; Schepis, F; Simoni, P; Villa, E; Vukotic, R, 2023) |
| "220 patients with known esophageal varices on upper GI endoscopy and no previous history of GI bleed were randomized to group A (Carvedilol) and group B (Propranolol)." | 3.30 | Comparison of carvedilol and propranolol for primary prophylaxis of esophageal variceal bleed in cirrhotic patients. ( Aneeza Ilyas, -; Khalid Mahmud Khan, -; Maria, -; Muhammad Adnan Iqbal, -; Muhammad Farooq Hanif, -; Nooman Gilani, -; Raja Omer Fiaz, -, 2023) |
| "Carvedilol is a non-selective beta-blocker (NSBB) acting on hyperdynamic circulation/splanchnic vasodilation and on intrahepatic resistance." | 3.01 | Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension. ( La Mura, V; Reiberger, T; Turco, L; Vitale, G, 2023) |
| "Carvedilol is a rising nonselective beta-blocker used for reducing portal pressure with favorable outcome." | 2.87 | Efficacy of carvedilol versus propranolol versus variceal band ligation for primary prevention of variceal bleeding. ( Abd ElRahim, AY; Elsharkawy, A; Fathalah, W; Fouad, R; Khairy, M; Khatamish, H; Khorshid, O; Moussa, M; Seyam, M, 2018) |
| "Propranolol has been used as prophylaxis for variceal bleeding in patients with cirrhosis." | 2.82 | A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis. ( Baik, SK; Jang, JY; Jeong, SW; Kim, DJ; Kim, MY; Kim, SG; Kim, TY; Kim, YS; Lee, B; Seo, YS; Sohn, JH; Suk, KT; Um, SH, 2016) |
| "Cirrhotics with large gastroesophageal varices type 2 with eradicated esophageal varices or large isolated gastric varix type 1, who had never bled from gastric varix, were randomised to cyanoacrylate injection (Group I, n=30), beta-blockers (Group II, n=29) or no treatment (Group III, n=30)." | 2.76 | Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers: a randomized controlled trial. ( Kumar, A; Mishra, SR; Sarin, SK; Sharma, BC, 2011) |
| "Primary end points were recurrence of variceal bleeding or death." | 2.75 | Equal efficacy of endoscopic variceal ligation and propranolol in preventing variceal bleeding in patients with noncirrhotic portal hypertension. ( Agrawal, A; Gupta, N; Jha, SK; Kumar, A; Mishra, SR; Sarin, SK; Sharma, BC, 2010) |
| "Bleeding from gastric varices is often severe and difficult to manage." | 2.75 | Endoscopic cyanoacrylate injection versus beta-blocker for secondary prophylaxis of gastric variceal bleed: a randomised controlled trial. ( Chander Sharma, B; Kumar, A; Mishra, SR; Sarin, SK, 2010) |
| "The obliteration of esophageal and/or gastric varices using Histoacryl is highly effective in controlling active bleeding." | 2.71 | Endoscopic histoacryl obliteration vs. propranolol in the prevention of esophagogastric variceal rebleeding: a randomized trial. ( Delhaye, M; Devière, J; Dumonceau, JM; Evrard, S; Golstein, P; Le Moine, O, 2003) |
| " In Gr I, incremental dosage of propranolol (sufficient to reduce heart rate to 55 beats/min or 25% reduction from baseline) was administered and continued after obliteration of varices." | 2.71 | Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding. ( Agarwal, SR; Sarin, SK; Sharma, BC; Tyagi, P; Wadhawan, M, 2005) |
| " Dosing of propranolol in the evening may be important for its role in preventing variceal bleeding." | 2.70 | Daily variation of azygos and portal blood flow and the effect of propranolol administration once an evening in cirrhotics. ( Ishii, K; Sasao, K; Sugano, S; Tanikawa, K; Watanabe, M; Yamamoto, K, 2001) |
| "Propranolol was well tolerated with minimal side effects in our patients with portal hypertension." | 2.69 | Propranolol in prevention of portal hypertensive hemorrhage in children: a pilot study. ( Grand, RJ; Langhans, N; Shashidhar, H, 1999) |
| "The incidence of clinically significant hepatic encephalopathy after 1 year was higher in the shunt group (36% vs 18%, p = 0." | 2.68 | Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. ( Blum, HE; Deibert, P; Geiger, R; Haag, K; Hauenstein, KH; Keller, W; Ochs, A; Olschewski, M; Rössle, M; Siegerstetter, V; Stiepak, C, 1997) |
| "Hepatic encephalopathy was observed in 29% of the patients in the TIPS group and in 13% of those in the ES group (P = 0." | 2.68 | Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. ( Benz, C; Richter, GM; Sauer, P; Stiehl, A; Stremmel, W; Theilmann, L, 1997) |
| "Eighteen cirrhotic patients with esophageal varices at risk for bleeding took part in a double-blind study." | 2.67 | Duplex Doppler ultrasonographic comparison of the effects of propranolol and isosorbide-5-mononitrate on portal hemodynamics. ( Abbati, G; Cioni, G; Cristani, A; D'Alimonte, P; Romagnoli, R; Tincani, E; Ventura, E; Ventura, P; Vignoli, A, 1993) |
| " The present study was aimed at comparing the efficacy of endoscopic sclerotherapy and long-term administration of propranolol in the prevention of rebleeding and long-term survival in patients who had bled from varices." | 2.67 | Propranolol versus sclerotherapy in preventing variceal rebleeding: a randomized controlled trial. ( Bordas, JM; Bosch, J; Cirera, I; Feu, F; Garcia Pagán, JC; Rodés, J; Terés, J, 1993) |
| "Propranolol was given orally twice a day until heart rate was reduced by 25% in the resting position." | 2.67 | Propranolol in the prevention of recurrent upper gastrointestinal bleeding in patients with cirrhosis undergoing endoscopic sclerotherapy. A randomized controlled trial. ( Avgerinos, A; Gouma, P; Klonis, C; Papadimitriou, N; Pournaras, S; Raptis, S; Rekoumis, G, 1993) |
| "Bleeding recurrence was less frequent in the treated patients (Kaplan Meier analysis p < 0." | 2.67 | [Prevention of digestive hemorrhage recurrence in hepatic cirrhosis with propranolol. A 4 years' follow-up study]. ( Armas, R; Jirón, MI; Soto, JR; Wolff, C, 1993) |
| "Propranolol dose was adjusted to reduce the resting heart rate by 25% of the basal value (mean +/- SD, 194." | 2.67 | Endoscopic sclerotherapy versus propranolol in prevention of recurrent variceal bleeding in patients with child's B and C cirrhosis: a preliminary report. ( Bhargava, DK; Dwivedi, M; Ramachandran, K, 1992) |
| "When considering only rebleedings from esophageal varices, 4 patients rebled in group 2 vs." | 2.67 | Propranolol reduces the rebleeding rate during endoscopic sclerotherapy before variceal obliteration. ( Barjonet, G; Barjonnet, G; Cales, P; Combis, JM; Desmorat, H; Lamouliatte, H; Pradere, B; Quinton, A; Roux, D; Vinel, JP, 1992) |
| "Propranolol-treated patients had fewer episodes of acute bleeding than controls (0." | 2.67 | Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. ( Bosch, J; González, A; Panés, J; Pérez, R; Pérez-Ayuso, RM; Piqué, JM; Quintero, E; Rigau, J; Valderrama, R; Viver, J, 1991) |
| "Propranolol was given twice daily with a mean final dose of 54 +/- 16 mg/day, this resulted in a mean reduction in resting heart rate of 26 +/- 7%." | 2.67 | Prevention of recurrent variceal bleeding in alcoholic cirrhotic patients: prospective controlled trial of propranolol and sclerotherapy. ( Boyer, J; Burtin, P; Calès, P; Charneau, J; D'Aubigny, N; Joubaud, F; Person, B; Pujol, P; Rossi, V; Valentin, S, 1991) |
| " Daily dosage was determined by the administration of progressively increasing doses of propranolol with the hepatic vein catheter in place to achieve a 25% decrease in hepatic venous pressure gradient, a decrease in hepatic venous pressure gradient to less than 12 mm Hg or a decrease in resting heart rate to less than 55 beats/min." | 2.67 | Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial. The Boston-New Haven-Barcelona Portal Hypertension Study Group. ( Bosch, J; Conn, HO; Fisher, RL; Garcia-Tsao, G; Grace, ND; Groszmann, RJ; Matloff, DS; Navasa, M; Rodés, J; Wright, SC, 1991) |
| " Patients were chosen randomly to receive oral propranolol (in a dosage to reduce resting pulse rate by 25%) or to undergo long-term injection sclerotherapy." | 2.67 | A controlled trial of oral propranolol compared with injection sclerotherapy for the long-term management of variceal bleeding. ( Gimson, AE; Hayes, PC; Hayllar, K; Polson, RJ; Westaby, D; Williams, R, 1990) |
| "Study endpoints were severe recurrence of variceal hemorrhage or death." | 2.67 | Propranolol in the prevention of recurrent variceal hemorrhage in cirrhotic patients. A controlled trial. ( Birnie, GG; Carter, DC; Garden, OJ; Mills, PR; Murray, GD, 1990) |
| "Atenolol was given at a fixed dose of 100 mg per day." | 2.66 | Beta-blockade prevents recurrent gastrointestinal bleeding in well-compensated patients with alcoholic cirrhosis: a multicenter randomized controlled trial. ( Colombo, M; de Franchis, R; Dioguardi, N; Sangiovanni, A; Tommasini, M, 1989) |
| "Atenolol was given at a fixed dose of 100 mg/day." | 2.66 | Beta-blockers in the secondary prevention of gastrointestinal haemorrhage in well-compensated cirrhotics. A multicentre randomised controlled study. ( Colombo, M; de Franchis, R; Sangiovanni, A; Tommasini, M, 1989) |
| "Propranolol is a useful medicament for the reduction of esophagic varices size and prevention of digestive bleeding in cirrhotic patients." | 2.66 | [Propranolol in the prevention of digestive bleeding in cirrhotic patients]. ( Castro, R; Glez Cansino, J; Sotto, A, 1989) |
| "This may in turn depend on the recurrence of bleeding." | 2.66 | Reduction in early recurrence of variceal bleeding by propranolol. ( Beglinger, C; Bögtlin, J; Gyr, KE; Kiowski, W; Loosli, J; Marbet, UA; Ritz, R; Schaub, N; Stalder, GA; Straumann, A, 1988) |
| "Propranolol dosage was titrated according to blood levels." | 2.66 | Systemic and hepatic hemodynamics after variceal hemorrhage: effects of propranolol and placebo. ( Huet, PM; Marleau, D; Pomier-Layrargues, G; Villeneuve, JP; Willems, B, 1987) |
| "Recent advances in the pharmacologic treatment of portal hypertension have mainly focused on modifying an increased intrahepatic resistance through nitric oxide and/or modulation of vasoactive substances." | 2.61 | Pharmacologic Management of Portal Hypertension. ( Bunchorntavakul, C; Reddy, KR, 2019) |
| "Frequently, relevant liver fibrosis is diagnosed by non-invasive methods (e." | 2.58 | [Management of compensated liver cirrhosis 2018 - Evidence based prophylactic measures]. ( Benten, D; Karkmann, K; Kluwe, J; Piecha, F; Rünzi, AC; Schulz, L; von Wulffen, M; Wege, H, 2018) |
| "According to their location, gastric varices (GV) are classified as gastroesophageal varices and isolated gastric varices." | 2.50 | Management of gastric varices. ( Barrufet, M; Cardenas, A; Escorsell, A; Garcia-Pagán, JC, 2014) |
| "Bacterial infections have been hypothetized to be a trigger of variceal bleeding in cirrhotic patients and beta-blockers may have a protective effect by decreasing bacterial translocation, reducing portal pressure." | 2.45 | beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. ( Burra, P; Burroughs, AK; Cholongitas, E; Leandro, G; Patch, D; Senzolo, M; Thalheimer, U, 2009) |
| "Terlipressin has longer effects and is more effective and safer than vasopressin alone or in combination with nitroglycerin." | 2.41 | The sixth Carlos E. Rubio Memorial Lecture. Prevention and treatment of variceal hemorrhage. ( Bosch, J, 2000) |
| "Hemorrhage from esophageal varices is a life-threatening event in patients with liver cirrhosis." | 2.39 | Beta-blockers for prophylaxis of bleeding from esophageal varices in cirrhotic portal hypertension. Review of the literature. ( Gross, M; Zoller, WG, 1996) |
| "The best results obtained in treatment of portal hypertension were: esophagogastric devascularization and splenectomy (EGDS), although risk of rebleeding persists; classical (proximal) splenorenal shunt (SRS) should be abandoned; distal splenorenal shunt may complicate with hepatic encephalopathy, although later and in a lower percentage than in SRS." | 2.38 | Portal hypertension in schistosomiasis: pathophysiology and treatment. ( Da Silva, LC, 1992) |
| "Bleeding from esophagogastric varices carries a high mortality rate." | 2.38 | Bleeding esophagogastric varices. Ways to treat active episodes and prevent recurrence. ( Marshall, JB, 1991) |
| "Only about one third of patients with esophageal varices eventually bleed." | 2.38 | [Treatment of hemorrhage of esophageal varices]. ( Sauerbruch, T, 1990) |
| "The development of bleeding esophagogastric varices and the methods used to treat this complication are all unsatisfactory either in the short or long term." | 2.37 | Theoretical and practical considerations in the treatment of portal hypertension secondary to hepatic cirrhosis. ( Bizer, LS, 1984) |
| "The cause of recurrent bleeding was esophageal varices in nine patients and esophageal ulcers in five patients." | 2.37 | [Sclerotherapy of esophageal varices using ethanol in combination with propranolol: clinical study of 30 patients]. ( Aubert, A; Chaput, JC; Lemman, M; Naveau, S; Poynard, T, 1988) |
| "Bleeding from esophageal varices remains a difficult clinical problem, carrying a high likelihood both of rebleeding and of mortality." | 2.37 | Management of the patient with hemorrhaging esophageal varices. ( Cello, JP; Crass, RA; Grendell, JH; Trunkey, DD, 1986) |
| "Peptic ulcer disease, oesophageal varices and Mallory-Weiss tear are the major causes." | 2.36 | Management of upper gastrointestinal haemorrhage. ( Korman, MG, 1983) |
| "Propranolol is a non-selective beta-blocker used as secondary prophylaxis for UVB, but no previous studies have addressed carvedilol effects in rebleeding prevention." | 1.72 | Carvedilol as secondary prophylaxis for variceal bleeding in hepatosplenic schistosomiasis. ( Cançado, GGL; Cardoso, JB; Couto, CA; de Abreu, ES; Faria, LC; Ferrari, TCA; Lima, AMC; Nardelli, MJ; Osório, FMF, 2022) |
| "Her pregnancy was uneventful until 31 weeks gestation when she presented with dyspnoea." | 1.48 | Pregnancy in a patient with portal hypertension secondary to liver cirrhosis. ( Lelei-Mailu, FJ; Mariara, CM, 2018) |
| "Hemangiomas are the most common benign tumors of the liver." | 1.43 | Hepatic Hemangioma with Kasabach-Merritt Syndrome in an Adult Patient. ( Cho, EA; Cho, SB; Choi, SK; Joo, YE; Jun, CH; Kim, HS; Lee, DH; Oak, CY; Park, CH; Rew, JS, 2016) |
| "Propranolol was associated with reduction in bleeding episodes (P < 0." | 1.42 | Extrahepatic portal vein obstruction in Egyptian children. ( El-Karaksy, HM; El-Koofy, N; El-Shabrawi, M; Helmy, H; Mohsen, N; Nabil, N, 2015) |
| "Propranolol has been reported to be used as a successful treatment of severe symptomatic infantile haemangiomas." | 1.40 | A complication to be aware of: hyperkalaemia following propranolol therapy for an infant with intestinal haemangiomatozis. ( Belen, B; Dalgic, B; Oguz, A; Okur, A, 2014) |
| " We aimed to evaluate the dosing and tolerance of BBs achievable in a specialized, nurse-run BB titration clinic with non-trial participants." | 1.36 | A specialized, nurse-run titration clinic: a feasible option for optimizing beta-blockade in non-clinical trial patients. ( Abraldes, JG; Berzigotti, A; Bosch, J; Garcia-Pagan, JC; Saez, R; Tandon, P, 2010) |
| "All of them had high-risk esophageal varices at endoscopy." | 1.35 | Propranolol reduces variceal pressure and wall tension in schistosomiasis presinusoidal portal hypertension. ( Bittencourt, PL; Carrilho, FJ; da Rocha, EC; Dos Santos Bomfim, V; Farias, AQ; Kassab, F; Vezozzo, DC, 2009) |
| "Such varices are often the source of difficult-to-treat recurrent or chronic bleeding." | 1.33 | Chronic stomal variceal bleeding after colonic surgery in patients with portal hypertension: efficacy of beta-blocking agents? ( Detry, RJ; Douala, HC; Druez, PM; Geubel, AP; Kartheuser, AH; Kartheuzer, AH; Noubibou, M, 2006) |
| "The variceal recurrence rate was 65 and 38." | 1.32 | Long-term outcome after sclerotherapy with or without a beta-blocker for variceal bleeding in children. ( Elkabes, B; Saner, G; Sökücü, S; Süoglu, OD, 2003) |
| "Ectopic intestinal varices are rarely responsible for lower gastrointestinal (GI) haemorrhage." | 1.32 | Ectopic intestinal varices as a rare cause of lower gastrointestinal haemorrhage. ( Ahmed, I; Alam, A; Alvi, A; Butt, AK; Khan, AA; Niazi, A; Sarwar, S; Shafqat, F; Tarique, S, 2003) |
| "Management of patients with bleeding oesophageal varices comprises of mainly diagnostic endoscopy, sclerotherapy and band ligation." | 1.32 | Can somatostatin control acute bleeding from oesophageal varices in Schistosoma mansoni patients?[ISRCTN63456799]. ( Chatterjee, S; Van Marck, E, 2004) |
| "Larger gastric varices have been shown to be the only risk factor for rebleeding (adjusted odds ratio, 4." | 1.31 | Pharmacologic efficacy in gastric variceal rebleeding and survival: including multivariate analysis. ( Chen, GH; Wu, CY; Yeh, HZ, 2002) |
| "The results of esophageal varices treatment in two groups of patients are shown." | 1.28 | [Sclerosing treatment of esophageal varices]. ( Jorge, AD; Milutin, C; Oliver, J, 1991) |
| "The so-called "low T3 syndrome" has frequently been reported in patients with cirrhosis." | 1.28 | "Low T3 syndrome" in cirrhosis: effect of beta-blockade. ( Bellanova, B; Bernardi, M; De Palma, R; Gasbarrini, G; Pesa, O; Tame, MR; Trevisani, F; Vecchi, F, 1989) |
| "Since the gastritis is related to vascular changes and congestion of the stomach wall secondary to increased portal pressure, and not inflammation, measures aimed at local healing or surgical removal of the bleeding area fail." | 1.27 | Persistent hemorrhagic gastritis in a patient with portal hypertension and esophagogastric varices: the role of portal decompressive surgery. ( Babb, RR; Mitchell, RL, 1988) |
| "Sclerotherapy of esophageal varices consists in obstruction of the varicosities." | 1.27 | [Prevention of recurrent hemorrhage due to portal hypertension]. ( Lebrec, D, 1986) |
| "100) rebled from esophageal varices within a mean time of 8." | 1.27 | [Propranolol prevention of hemorrhagic recurrence caused by rupture of esophageal varices: worsened prognosis in ascites and jaundice]. ( Attali, P; Buffet, C; Etienne, JP; Ink, O; Pelletier, G; Servent, L, 1985) |
| "Propranolol was administered to 5 patients, in doses of 60-80 mg daily." | 1.26 | Injection sclerotherapy of esophageal varices. ( Jorge, AD, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 98 (30.06) | 18.7374 |
| 1990's | 100 (30.67) | 18.2507 |
| 2000's | 62 (19.02) | 29.6817 |
| 2010's | 49 (15.03) | 24.3611 |
| 2020's | 17 (5.21) | 2.80 |
| Authors | Studies |
|---|---|
| de Abreu, ES | 1 |
| Nardelli, MJ | 1 |
| Lima, AMC | 1 |
| Cardoso, JB | 1 |
| Osório, FMF | 1 |
| Ferrari, TCA | 1 |
| Faria, LC | 1 |
| Couto, CA | 1 |
| Cançado, GGL | 1 |
| Mao, G | 1 |
| Li, C | 1 |
| Wang, H | 2 |
| Jv, YH | 1 |
| Zhang, Y | 1 |
| Liu, L | 1 |
| Singh, V | 1 |
| Kumar, P | 1 |
| Verma, N | 1 |
| Vijayvergiya, R | 1 |
| Singh, A | 1 |
| Bhalla, A | 1 |
| Nabilou, P | 1 |
| Danielsen, KV | 1 |
| Kimer, N | 1 |
| Hove, JD | 1 |
| Bendtsen, F | 3 |
| Møller, S | 1 |
| Hofer, BS | 1 |
| Simbrunner, B | 2 |
| Bauer, DJM | 1 |
| Paternostro, R | 2 |
| Schwabl, P | 3 |
| Scheiner, B | 2 |
| Semmler, G | 1 |
| Hartl, L | 2 |
| Jachs, M | 2 |
| Datterl, B | 1 |
| Staettermayer, AF | 1 |
| Trauner, M | 4 |
| Mandorfer, M | 3 |
| Reiberger, T | 6 |
| Bauer, D | 1 |
| Balcar, L | 1 |
| Hofer, B | 1 |
| Pfisterer, N | 1 |
| Schwarz, M | 1 |
| Stättermayer, AF | 1 |
| Pinter, M | 3 |
| Chakraborty, A | 1 |
| Beasley, G | 1 |
| Martinez, H | 1 |
| Jesudas, R | 1 |
| Anton-Martin, P | 1 |
| Christakopoulos, G | 1 |
| Kramer, J | 2 |
| Turco, L | 1 |
| Vitale, G | 2 |
| La Mura, V | 1 |
| Tapper, EB | 1 |
| Parikh, ND | 1 |
| Vukotic, R | 2 |
| Di Donato, R | 1 |
| Roncarati, G | 1 |
| Simoni, P | 1 |
| Renzulli, M | 1 |
| Gitto, S | 1 |
| Schepis, F | 1 |
| Villa, E | 1 |
| Berzigotti, A | 2 |
| Bosch, J | 14 |
| Andreone, P | 2 |
| Muhammad Farooq Hanif, - | 1 |
| Raja Omer Fiaz, - | 1 |
| Muhammad Adnan Iqbal, - | 1 |
| Aneeza Ilyas, - | 1 |
| Maria, - | 1 |
| Khalid Mahmud Khan, - | 1 |
| Nooman Gilani, - | 1 |
| Wang, X | 1 |
| Liu, G | 1 |
| Wu, J | 1 |
| Xiao, X | 1 |
| Yan, Y | 1 |
| Guo, Y | 1 |
| Yang, J | 1 |
| Li, X | 4 |
| He, Y | 1 |
| Yang, L | 1 |
| Luo, X | 1 |
| Bunchorntavakul, C | 1 |
| Reddy, KR | 1 |
| Yoo, JJ | 1 |
| Kim, SG | 3 |
| Kim, YS | 3 |
| Lee, B | 2 |
| Jeong, SW | 3 |
| Jang, JY | 3 |
| Lee, SH | 2 |
| Kim, HS | 3 |
| Jun, BG | 1 |
| Kim, YD | 1 |
| Cheon, GJ | 1 |
| Raimondi, F | 1 |
| Brodosi, L | 1 |
| Petroni, ML | 1 |
| Marchesini, G | 1 |
| Shao, R | 1 |
| Li, Z | 1 |
| Wang, J | 2 |
| Qi, R | 1 |
| Liu, Q | 1 |
| Zhang, W | 3 |
| Mao, X | 1 |
| Song, X | 1 |
| Li, L | 1 |
| Liu, Y | 1 |
| Zhao, X | 1 |
| Liu, C | 1 |
| Zuo, C | 1 |
| Wang, W | 1 |
| Qi, X | 3 |
| Afaa, TJ | 1 |
| Amegan-Aho, KH | 1 |
| Richardson, E | 1 |
| Goka, B | 1 |
| Grammatikopoulos, T | 1 |
| McKiernan, PJ | 1 |
| Dhawan, A | 1 |
| Lv, Y | 1 |
| He, C | 1 |
| Wang, Z | 1 |
| Yin, Z | 1 |
| Niu, J | 1 |
| Guo, W | 1 |
| Bai, W | 1 |
| Zhang, H | 1 |
| Xie, H | 1 |
| Yao, L | 1 |
| Li, T | 2 |
| Wang, Q | 1 |
| Chen, H | 1 |
| Liu, H | 1 |
| Wang, E | 1 |
| Xia, D | 1 |
| Luo, B | 1 |
| Yuan, J | 1 |
| Han, N | 1 |
| Zhu, Y | 1 |
| Xia, J | 1 |
| Cai, H | 1 |
| Yang, Z | 1 |
| Wu, K | 1 |
| Fan, D | 2 |
| Han, G | 2 |
| Püspök, A | 1 |
| Schoder, M | 1 |
| Baumann-Durchschein, F | 1 |
| Bucsics, T | 1 |
| Datz, C | 1 |
| Dolak, W | 1 |
| Ferlitsch, A | 3 |
| Finkenstedt, A | 1 |
| Graziadei, I | 1 |
| Hametner, S | 1 |
| Karnel, F | 1 |
| Krones, E | 1 |
| Maieron, A | 1 |
| Peck-Radosavljevic, M | 3 |
| Rainer, F | 1 |
| Stadlbauer, V | 1 |
| Stauber, R | 1 |
| Tilg, H | 1 |
| Zoller, H | 1 |
| Schöfl, R | 1 |
| Fickert, P | 1 |
| Abd ElRahim, AY | 1 |
| Fouad, R | 1 |
| Khairy, M | 1 |
| Elsharkawy, A | 1 |
| Fathalah, W | 1 |
| Khatamish, H | 1 |
| Khorshid, O | 1 |
| Moussa, M | 1 |
| Seyam, M | 1 |
| Baiges, A | 1 |
| Hernández-Gea, V | 2 |
| Stark, C | 1 |
| Kiss, J | 1 |
| Lemström, K | 1 |
| Karkmann, K | 1 |
| Piecha, F | 1 |
| Rünzi, AC | 1 |
| Schulz, L | 1 |
| von Wulffen, M | 1 |
| Benten, D | 1 |
| Kluwe, J | 1 |
| Wege, H | 1 |
| Robertson, M | 1 |
| Hayes, P | 3 |
| Lelei-Mailu, FJ | 1 |
| Mariara, CM | 1 |
| Zacharias, AP | 1 |
| Jeyaraj, R | 1 |
| Hobolth, L | 1 |
| Gluud, LL | 1 |
| Morgan, MY | 1 |
| Zhang, F | 1 |
| Xu, H | 1 |
| Chen, M | 1 |
| Zhang, M | 2 |
| Xiao, J | 1 |
| Wang, Y | 1 |
| He, Q | 1 |
| Yin, X | 1 |
| Zou, X | 1 |
| Zhuge, Y | 1 |
| Krick, J | 1 |
| Riehle, K | 1 |
| Chapman, T | 1 |
| Chabra, S | 1 |
| Li, LN | 1 |
| Sun, XY | 1 |
| Wang, GC | 1 |
| Tian, XG | 1 |
| Zhang, MY | 1 |
| Jiang, KT | 1 |
| Zhang, CQ | 1 |
| Kim, BH | 1 |
| Chung, JW | 1 |
| Lee, CS | 1 |
| Jang, ES | 1 |
| Jeong, SH | 1 |
| Kim, N | 1 |
| Kim, JW | 1 |
| Villanueva, C | 2 |
| Albillos, A | 1 |
| Genescà, J | 1 |
| Garcia-Pagan, JC | 5 |
| Calleja, JL | 1 |
| Aracil, C | 2 |
| Bañares, R | 2 |
| Morillas, RM | 1 |
| Poca, M | 1 |
| Peñas, B | 1 |
| Augustin, S | 1 |
| Abraldes, JG | 2 |
| Alvarado, E | 1 |
| Torres, F | 1 |
| Kong, DR | 2 |
| Ma, C | 1 |
| Wang, M | 1 |
| Wang, JG | 2 |
| Chen, C | 2 |
| Zhang, L | 1 |
| Hao, JH | 1 |
| Li, P | 1 |
| Xu, JM | 2 |
| Barrufet, M | 1 |
| Cardenas, A | 1 |
| Escorsell, A | 3 |
| Bai, M | 1 |
| Yang, M | 1 |
| Choi, MH | 1 |
| Lee, YN | 1 |
| Seo, YR | 1 |
| Kim, MJ | 1 |
| Kim, BS | 1 |
| Belen, B | 1 |
| Oguz, A | 1 |
| Okur, A | 1 |
| Dalgic, B | 1 |
| Je, D | 1 |
| Paik, YH | 1 |
| Gwak, GY | 1 |
| Choi, MS | 1 |
| Lee, JH | 1 |
| Koh, KC | 1 |
| Paik, SW | 1 |
| Yoo, BC | 1 |
| Bonilha, DQ | 1 |
| Lenz, L | 1 |
| Correia, LM | 1 |
| Rodrigues, RA | 1 |
| de Paulo, GA | 1 |
| Ferrari, AP | 1 |
| Della Libera, E | 1 |
| El-Karaksy, HM | 1 |
| El-Koofy, N | 1 |
| Mohsen, N | 1 |
| Helmy, H | 1 |
| Nabil, N | 1 |
| El-Shabrawi, M | 1 |
| Sauerbruch, T | 6 |
| Mengel, M | 1 |
| Dollinger, M | 1 |
| Zipprich, A | 1 |
| Rössle, M | 3 |
| Panther, E | 1 |
| Wiest, R | 1 |
| Caca, K | 1 |
| Hoffmeister, A | 1 |
| Lutz, H | 1 |
| Schoo, R | 1 |
| Lorenzen, H | 1 |
| Trebicka, J | 1 |
| Appenrodt, B | 1 |
| Schepke, M | 3 |
| Fimmers, R | 1 |
| Korsaga-Somé, N | 1 |
| Maruani, A | 1 |
| Abdo, I | 1 |
| Favrais, G | 1 |
| Lorette, G | 1 |
| Sun, B | 1 |
| Wang, MQ | 1 |
| Yu, FF | 1 |
| Oak, CY | 1 |
| Jun, CH | 1 |
| Cho, EA | 1 |
| Lee, DH | 1 |
| Cho, SB | 1 |
| Park, CH | 1 |
| Joo, YE | 1 |
| Rew, JS | 1 |
| Choi, SK | 1 |
| Ke, W | 1 |
| Sun, P | 1 |
| Chen, X | 1 |
| Belgaumkar, A | 1 |
| Huang, Y | 1 |
| Xian, W | 1 |
| Li, J | 1 |
| Zheng, Q | 1 |
| Wang, G | 1 |
| Zhao, L | 1 |
| Wu, Z | 1 |
| Zhang, C | 1 |
| Kim, TY | 1 |
| Sohn, JH | 1 |
| Um, SH | 1 |
| Seo, YS | 1 |
| Baik, SK | 1 |
| Kim, MY | 1 |
| Suk, KT | 1 |
| Kim, DJ | 2 |
| Gupta, V | 1 |
| Rawat, R | 1 |
| Saraya, A | 1 |
| Shukla, R | 1 |
| Cao, Y | 1 |
| Ying, J | 1 |
| Tansel, A | 1 |
| Walder, A | 1 |
| Advani, S | 1 |
| El-Serag, HB | 1 |
| Kanwal, F | 1 |
| Steib, CJ | 1 |
| Gerbes, AL | 1 |
| Lebrec, L | 1 |
| Colomo, A | 1 |
| López-Balaguer, JM | 1 |
| Alvarez-Urturi, C | 1 |
| Torras, X | 1 |
| Balanzó, J | 1 |
| Guarner, C | 1 |
| Sharma, P | 2 |
| Kumar, A | 5 |
| Sharma, BC | 5 |
| Sarin, SK | 8 |
| Ahmad, I | 1 |
| Khan, AA | 2 |
| Alam, A | 2 |
| Butt, AK | 2 |
| Shafqat, F | 2 |
| Sarwar, S | 2 |
| Jha, SK | 2 |
| Dubey, S | 1 |
| Tyagi, P | 2 |
| Senzolo, M | 3 |
| Cholongitas, E | 2 |
| Burra, P | 2 |
| Leandro, G | 1 |
| Thalheimer, U | 3 |
| Patch, D | 3 |
| Burroughs, AK | 8 |
| Farias, AQ | 1 |
| Kassab, F | 1 |
| da Rocha, EC | 1 |
| Dos Santos Bomfim, V | 1 |
| Vezozzo, DC | 1 |
| Bittencourt, PL | 1 |
| Carrilho, FJ | 1 |
| Fries, W | 1 |
| Buda, A | 1 |
| Pizzuti, D | 1 |
| Nadal, E | 1 |
| Sturniolo, GC | 1 |
| D'Incà, R | 1 |
| Gupta, N | 1 |
| Agrawal, A | 1 |
| Mishra, SR | 3 |
| Chander Sharma, B | 1 |
| Tandon, P | 1 |
| Saez, R | 1 |
| Thevenot, T | 1 |
| Cervoni, JP | 1 |
| Di Martino, V | 1 |
| Lo, GH | 2 |
| Talwalkar, JA | 1 |
| Catalina, MV | 1 |
| Ripoll, C | 1 |
| Rincón, D | 1 |
| Ko, SY | 1 |
| Kim, JH | 1 |
| Choe, WH | 1 |
| Kwon, SY | 1 |
| Lee, CH | 1 |
| Payer, BA | 2 |
| Homoncik, M | 1 |
| Feng, C | 1 |
| Huang, F | 1 |
| Nie, W | 1 |
| Liu, X | 1 |
| Ren, S | 1 |
| Chaudhuri, K | 1 |
| Tan, EK | 1 |
| Biswas, A | 2 |
| Baran, M | 1 |
| Kanik, A | 1 |
| Can, E | 1 |
| Parildar, M | 1 |
| Pala, EE | 1 |
| Helvaci, M | 1 |
| Ulbrich, G | 1 |
| Heinisch, BB | 1 |
| Kramer, L | 1 |
| Wu, CY | 1 |
| Yeh, HZ | 1 |
| Chen, GH | 1 |
| Lui, HF | 1 |
| Stanley, AJ | 1 |
| Forrest, EH | 1 |
| Jalan, R | 1 |
| Hislop, WS | 2 |
| Mills, PR | 3 |
| Finlayson, ND | 1 |
| Macgilchrist, AJ | 1 |
| Hayes, PC | 6 |
| Bureau, C | 1 |
| Péron, JM | 1 |
| Alric, L | 1 |
| Morales, J | 1 |
| Sanchez, J | 1 |
| Barange, K | 1 |
| Payen, JL | 1 |
| Vinel, JP | 3 |
| Zhang, Q | 1 |
| Yuan, R | 1 |
| Orban-Schiopu, AM | 1 |
| Popescu, CR | 1 |
| Blendis, L | 1 |
| Lurie, Y | 1 |
| Oren, R | 1 |
| Mann, NS | 1 |
| Sökücü, S | 1 |
| Süoglu, OD | 1 |
| Elkabes, B | 1 |
| Saner, G | 1 |
| Cheng, JW | 1 |
| Zhu, L | 1 |
| Gu, MJ | 1 |
| Song, ZM | 1 |
| Evrard, S | 1 |
| Dumonceau, JM | 1 |
| Delhaye, M | 1 |
| Golstein, P | 1 |
| Devière, J | 1 |
| Le Moine, O | 1 |
| Tarique, S | 1 |
| Ahmed, I | 1 |
| Alvi, A | 1 |
| Niazi, A | 1 |
| Nidegger, D | 1 |
| Ragot, S | 1 |
| Berthelémy, P | 1 |
| Masliah, C | 3 |
| Pilette, C | 1 |
| Martin, T | 4 |
| Bianchi, A | 1 |
| Paupard, T | 1 |
| Silvain, C | 2 |
| Beauchant, M | 3 |
| Schiedermaier, P | 1 |
| Koch, L | 2 |
| Stoffel-Wagner, B | 1 |
| Layer, G | 1 |
| Tomikawa, M | 1 |
| Shimabukuro, R | 1 |
| Okita, K | 1 |
| Tsutsumi, N | 1 |
| Akahoshi, T | 1 |
| Hashizume, M | 1 |
| Sugimachi, K | 1 |
| Kleber, G | 1 |
| Nürnberg, D | 1 |
| Willert, J | 1 |
| Veltzke-Schlieker, W | 1 |
| Hellerbrand, C | 1 |
| Kuth, J | 1 |
| Schanz, S | 1 |
| Kahl, S | 1 |
| Fleig, WE | 1 |
| Bhaskar, ME | 1 |
| Krikis, N | 1 |
| Tziomalos, K | 1 |
| Perifanis, V | 1 |
| Vakalopoulou, S | 1 |
| Karagiannis, A | 1 |
| Garipidou, V | 1 |
| Harsoulis, F | 1 |
| Chatterjee, S | 1 |
| Van Marck, E | 1 |
| Hsu, DZ | 1 |
| Wang, ST | 1 |
| Deng, JF | 1 |
| Liu, MY | 1 |
| Wadhawan, M | 2 |
| Agarwal, SR | 1 |
| Chalasani, N | 1 |
| Boyer, TD | 2 |
| Jutabha, R | 1 |
| Jensen, DM | 1 |
| Martin, P | 1 |
| Savides, T | 1 |
| Han, SH | 1 |
| Gornbein, J | 1 |
| Gawrieh, S | 1 |
| Shaker, R | 1 |
| Gupta, R | 1 |
| Shahi, H | 1 |
| Psilopoulos, D | 1 |
| Galanis, P | 1 |
| Goulas, S | 1 |
| Papanikolaou, IS | 1 |
| Elefsiniotis, I | 1 |
| Liatsos, C | 1 |
| Sparos, L | 1 |
| Mavrogiannis, C | 1 |
| De Madaria, E | 1 |
| Palazón, JM | 1 |
| Pérez-Mateo, M | 1 |
| Triantos, C | 1 |
| Vlachogiannakos, J | 2 |
| Manolakopoulos, S | 2 |
| Burroughs, A | 1 |
| Avgerinos, A | 3 |
| Lay, CS | 1 |
| Tsai, YT | 1 |
| Lee, FY | 1 |
| Lai, YL | 1 |
| Yu, CJ | 1 |
| Chen, CB | 1 |
| Peng, CY | 1 |
| Garrido, A | 1 |
| Márquez, JL | 1 |
| Iglesias, A | 1 |
| Peiró, J | 1 |
| Grilo, I | 1 |
| Garzón, M | 1 |
| Noubibou, M | 1 |
| Douala, HC | 1 |
| Druez, PM | 1 |
| Kartheuser, AH | 1 |
| Kartheuzer, AH | 1 |
| Detry, RJ | 1 |
| Geubel, AP | 1 |
| van der Wouden, EJ | 1 |
| Westerveld, BD | 1 |
| Youn, KH | 1 |
| Laleman, W | 1 |
| Nevens, F | 4 |
| Marelli, L | 1 |
| Norberto, L | 1 |
| Polese, L | 1 |
| Cillo, U | 1 |
| Grigoletto, F | 1 |
| Neri, D | 1 |
| Zanus, G | 1 |
| Boccagni, P | 1 |
| D'Amico, DF | 1 |
| Charpignon, C | 1 |
| Oberti, F | 2 |
| Bernard, P | 1 |
| Bartoli, ER | 1 |
| Pauwels, A | 1 |
| Renard, P | 1 |
| Cadranel, JF | 1 |
| Bernard-Chabert, B | 1 |
| Barbare, JC | 1 |
| Ingrand, I | 1 |
| Ingrand, P | 1 |
| Kovacević, N | 1 |
| Tomić, D | 1 |
| Perisić-Savić, M | 1 |
| Grbić, R | 1 |
| De, BK | 2 |
| Dutta, D | 1 |
| Som, R | 1 |
| Biswas, PK | 2 |
| Pal, SK | 1 |
| Lebrec, D | 15 |
| Nouel, O | 2 |
| Corbic, M | 1 |
| Benhamou, JP | 5 |
| Olsson, R | 1 |
| Hütteroth, TH | 1 |
| Meyer zum Büschenfelde, KH | 1 |
| Shepherd, AN | 1 |
| Bouchier, IA | 4 |
| Joffe, SN | 1 |
| Rueff, B | 3 |
| Arnold, R | 1 |
| Poynard, T | 7 |
| Naveau, S | 2 |
| Poitrine, A | 1 |
| Lebourgeois, P | 1 |
| Hilpert, G | 1 |
| Chaput, JC | 2 |
| Jenkins, WJ | 2 |
| Sherlock, S | 2 |
| Dunk, A | 1 |
| Walt, RP | 2 |
| Osuafor, TO | 1 |
| Mackie, S | 1 |
| Dick, R | 1 |
| Reynolds, TB | 1 |
| Korman, MG | 1 |
| Bizer, LS | 1 |
| Dobrilla, G | 1 |
| de Pretis, G | 2 |
| Tarver, D | 1 |
| Dunk, AA | 1 |
| Resnick, RH | 1 |
| Larrey, D | 1 |
| Bercoff, E | 2 |
| Pessayre, D | 1 |
| Alabaster, SL | 1 |
| Gogel, HK | 2 |
| McCarthy, DM | 1 |
| Anderberg, B | 1 |
| Andersson, PA | 1 |
| Heuman, R | 1 |
| Jansson, L | 1 |
| Jorfeldt, L | 1 |
| Rutberg, H | 1 |
| Sjödahl, R | 1 |
| Ahmad, S | 1 |
| Bleichner, G | 1 |
| Parent, A | 1 |
| Raffray, Y | 1 |
| Squara, P | 1 |
| Chevrel, B | 1 |
| Jorge, AD | 2 |
| Bernuau, J | 2 |
| Maringhini, A | 1 |
| Simonetti, RM | 1 |
| Marcenò, MP | 1 |
| Pagliaro, L | 5 |
| Hillon, P | 1 |
| Feu, F | 4 |
| Luca, A | 2 |
| Terés, J | 2 |
| Rodés, J | 6 |
| Blanc, P | 1 |
| Shigemori, H | 1 |
| Iwao, T | 2 |
| Ikegami, M | 1 |
| Toyonaga, A | 2 |
| Tanikawa, K | 2 |
| Bołdys, H | 1 |
| Hartleb, M | 1 |
| Rudzki, K | 1 |
| Nowak, A | 1 |
| Nowak, S | 1 |
| el Tourabi, H | 1 |
| el Amin, AA | 1 |
| Shaheen, M | 1 |
| Woda, SA | 1 |
| Homeida, M | 1 |
| Harron, DW | 1 |
| Kitano, S | 1 |
| Tincani, E | 3 |
| Cioni, G | 4 |
| Cristani, A | 3 |
| D'Alimonte, P | 3 |
| Vignoli, A | 1 |
| Abbati, G | 1 |
| Ventura, P | 2 |
| Romagnoli, R | 2 |
| Ventura, E | 3 |
| Plevris, JN | 1 |
| Elliot, R | 1 |
| Davies, JM | 1 |
| Bordas, JM | 2 |
| Garcia Pagán, JC | 1 |
| Cirera, I | 1 |
| Van Stiegmann, G | 2 |
| Rekoumis, G | 2 |
| Klonis, C | 1 |
| Papadimitriou, N | 1 |
| Gouma, P | 1 |
| Pournaras, S | 1 |
| Raptis, S | 1 |
| Jirón, MI | 2 |
| Soto, JR | 1 |
| Wolff, C | 1 |
| Armas, R | 1 |
| Kanazawa, H | 2 |
| Watari, A | 2 |
| Tada, N | 2 |
| Matsusaka, S | 2 |
| Nakatsuka, K | 1 |
| Saitoh, H | 2 |
| Yoshizawa, M | 2 |
| Kuroda, H | 2 |
| Kobayashi, M | 2 |
| Nomura, T | 1 |
| Melissant, CF | 1 |
| Smith, SJ | 1 |
| Kazzaz, BA | 1 |
| Demedts, M | 1 |
| Rataboli, PV | 2 |
| Diniz D'Souza, RS | 1 |
| Dhume, VG | 2 |
| Angelico, M | 2 |
| Carli, L | 2 |
| Piat, C | 2 |
| Gentile, S | 2 |
| Rinaldi, V | 1 |
| Bologna, E | 1 |
| Capocaccia, L | 2 |
| Ferrer Feliu, A | 1 |
| Falguera, M | 1 |
| Reñé, JM | 1 |
| Barrett, AE | 1 |
| Navaratnam, RM | 1 |
| Lemberger, RJ | 1 |
| Turrini, F | 3 |
| Zoller, WG | 2 |
| Gross, M | 2 |
| Lijnen, P | 1 |
| VanBilloen, H | 1 |
| Fevery, J | 2 |
| Elsayed, SS | 1 |
| Shiha, G | 1 |
| Hamid, M | 1 |
| Farag, FM | 1 |
| Azzam, F | 1 |
| Awad, M | 1 |
| Sprengers, D | 1 |
| Urbistondo, M | 1 |
| Torres, EA | 1 |
| Castro, F | 1 |
| Oharriz, J | 1 |
| Medina, R | 1 |
| Molina, A | 1 |
| Marquez, E | 1 |
| Rubio, CE | 1 |
| Bernard, B | 1 |
| Mathurin, P | 1 |
| Opolon, P | 1 |
| Hermann, R | 1 |
| Deibert, P | 1 |
| Haag, K | 2 |
| Ochs, A | 1 |
| Olschewski, M | 1 |
| Siegerstetter, V | 1 |
| Hauenstein, KH | 1 |
| Geiger, R | 1 |
| Stiepak, C | 1 |
| Keller, W | 1 |
| Blum, HE | 1 |
| Sauer, P | 1 |
| Theilmann, L | 1 |
| Stremmel, W | 1 |
| Benz, C | 1 |
| Richter, GM | 1 |
| Stiehl, A | 1 |
| Alvarez, F | 1 |
| Lamba, GS | 1 |
| Kumar, M | 1 |
| Misra, A | 1 |
| Murthy, NS | 1 |
| Ghoshal, UC | 1 |
| Das, T | 1 |
| Santra, A | 1 |
| Schreiber, RA | 1 |
| Shashidhar, H | 1 |
| Langhans, N | 1 |
| Grand, RJ | 1 |
| Boldrini, E | 1 |
| Baraldi, E | 1 |
| Pedrazzini, PG | 1 |
| Green, JA | 1 |
| Amaro, R | 1 |
| Barkin, JS | 3 |
| Gournay, J | 1 |
| Perrin, D | 3 |
| Galmiche, JP | 1 |
| Armonis, A | 1 |
| Argirakis, G | 1 |
| Viazis, N | 1 |
| Adamopoulos, A | 1 |
| Kanaghinis, T | 1 |
| Raptis, SA | 1 |
| Chen, D | 1 |
| Zou, J | 1 |
| Deschênes, M | 1 |
| Barkun, AN | 1 |
| Assi, SA | 1 |
| Sanyal, A | 1 |
| Schubert, ML | 1 |
| Lowe, RC | 1 |
| Grace, ND | 4 |
| Sugano, S | 1 |
| Yamamoto, K | 1 |
| Sasao, K | 1 |
| Ishii, K | 1 |
| Watanabe, M | 1 |
| Lai, KH | 1 |
| Cheng, JS | 1 |
| Hsu, PI | 1 |
| Chen, TA | 1 |
| Wang, EM | 1 |
| Lin, CK | 1 |
| Chiang, HT | 1 |
| Zimmon, DS | 1 |
| Manheimer, F | 1 |
| Abraczinskas, DR | 1 |
| Ookubo, R | 1 |
| Groszmann, RJ | 3 |
| Garcia-Tsao, G | 3 |
| Richardson, CR | 1 |
| Matloff, DS | 2 |
| Conn, HO | 5 |
| Lee, SP | 1 |
| Tasman-Jones, C | 1 |
| Wattie, WJ | 1 |
| Da Silva, LC | 1 |
| Selub, S | 2 |
| Muñoz, SJ | 1 |
| Hamid, S | 1 |
| Jafri, W | 1 |
| Garden, OJ | 2 |
| Carter, DC | 2 |
| Ink, O | 3 |
| Reville, M | 1 |
| Anciaux, ML | 2 |
| Lenoir, C | 1 |
| Marill, JL | 1 |
| Labadie, H | 1 |
| Triger, DR | 2 |
| Dwivedi, M | 1 |
| Bhargava, DK | 1 |
| Ramachandran, K | 1 |
| Calès, P | 10 |
| Elder, CA | 1 |
| Restino, MS | 1 |
| Lamouliatte, H | 1 |
| Combis, JM | 1 |
| Roux, D | 1 |
| Desmorat, H | 1 |
| Pradere, B | 1 |
| Barjonet, G | 1 |
| Quinton, A | 1 |
| Barjonnet, G | 1 |
| Schwartz, J | 1 |
| Rozenfeld, V | 1 |
| Habot, B | 1 |
| Bhandare, PN | 1 |
| D'Souza, RS | 1 |
| Otaguro, JE | 1 |
| Hart, LL | 1 |
| Wruck, U | 1 |
| Wermke, W | 1 |
| Brady, CE | 1 |
| Jönson, C | 1 |
| Hamlet, A | 1 |
| Fändriks, L | 1 |
| Marshall, JB | 1 |
| Pasta, L | 3 |
| Ideo, G | 1 |
| Pascal, JP | 4 |
| Pérez-Ayuso, RM | 2 |
| Piqué, JM | 2 |
| Panés, J | 1 |
| González, A | 1 |
| Pérez, R | 1 |
| Rigau, J | 1 |
| Quintero, E | 1 |
| Valderrama, R | 1 |
| Viver, J | 1 |
| Hüppe, D | 1 |
| May, B | 1 |
| Taupignon, A | 1 |
| Lavignolle, A | 1 |
| Le Bodic, L | 1 |
| Milutin, C | 1 |
| Oliver, J | 1 |
| Geller, LI | 1 |
| Miyata, K | 1 |
| Rossi, V | 1 |
| Burtin, P | 1 |
| Charneau, J | 1 |
| Person, B | 1 |
| Pujol, P | 1 |
| Valentin, S | 1 |
| D'Aubigny, N | 1 |
| Joubaud, F | 1 |
| Boyer, J | 1 |
| Snady, H | 2 |
| Korula, J | 1 |
| Carey, WE | 1 |
| Davis, JM | 1 |
| Lewis, JA | 1 |
| Elta, GH | 1 |
| Wright, SC | 1 |
| Fisher, RL | 1 |
| Navasa, M | 2 |
| Cotton, P | 1 |
| Bhandare, P | 1 |
| Diniz-D'Souza, R | 1 |
| Mainker, A | 1 |
| Dhume, V | 1 |
| Westaby, D | 2 |
| Polson, RJ | 1 |
| Gimson, AE | 1 |
| Hayllar, K | 1 |
| Williams, R | 2 |
| Avezzano, ES | 1 |
| Seefe, LB | 1 |
| Alberts, J | 1 |
| Fischer, R | 1 |
| Bermann, M | 1 |
| Pfeffer, R | 1 |
| Reinus, JF | 1 |
| Andreani, T | 1 |
| Poupon, RE | 1 |
| Balkau, BJ | 1 |
| Trinchet, JC | 1 |
| Grange, JD | 1 |
| Peigney, N | 1 |
| Beaugrand, M | 1 |
| Poupon, R | 2 |
| Lundell, L | 1 |
| Leth, R | 1 |
| Lind, T | 1 |
| Lönroth, H | 1 |
| Sjövall, M | 1 |
| Olbe, L | 1 |
| Eugène, C | 1 |
| Vitte, RL | 1 |
| Qureshi, H | 1 |
| Zuberi, SJ | 1 |
| Alam, E | 1 |
| Jensen, LS | 2 |
| Krarup, N | 2 |
| Birnie, GG | 2 |
| Murray, GD | 1 |
| Kiire, CF | 1 |
| Toba, N | 1 |
| Honjou, I | 1 |
| Kadohara, M | 1 |
| Hirayama, C | 1 |
| Parelon, G | 1 |
| Guiry, P | 1 |
| Daures, JP | 1 |
| Bories, P | 1 |
| Feneyrou, B | 1 |
| Ampelas, M | 1 |
| Bauret, P | 1 |
| Aubin, JP | 1 |
| Prioton, JB | 1 |
| Michel, H | 1 |
| Colombo, M | 2 |
| de Franchis, R | 2 |
| Tommasini, M | 2 |
| Sangiovanni, A | 2 |
| Dioguardi, N | 1 |
| Braillon, A | 3 |
| Moreau, R | 1 |
| Hadengue, A | 1 |
| Roulot, D | 1 |
| Sayegh, R | 1 |
| Bondarenko, IP | 1 |
| Dubinskiĭ, AA | 1 |
| Tereshkin, IG | 1 |
| Sheen, IS | 1 |
| Chen, TY | 1 |
| Liaw, YF | 1 |
| Capron, JP | 1 |
| Bouvry, M | 1 |
| D'Amico, G | 2 |
| Sotto, A | 1 |
| Castro, R | 1 |
| Glez Cansino, J | 1 |
| O'Connor, KW | 1 |
| Lehman, G | 1 |
| Yune, H | 1 |
| Brunelle, R | 1 |
| Christiansen, P | 1 |
| Hast, J | 1 |
| Compton, M | 1 |
| McHenry, R | 1 |
| Klatte, E | 1 |
| Cockerill, E | 1 |
| Bernardi, M | 1 |
| De Palma, R | 1 |
| Trevisani, F | 1 |
| Pesa, O | 1 |
| Tame, MR | 1 |
| Bellanova, B | 1 |
| Vecchi, F | 1 |
| Gasbarrini, G | 1 |
| Rabeneck, L | 1 |
| Polson, R | 1 |
| Gimson, A | 1 |
| Dollet, JM | 2 |
| Champigneulle, B | 2 |
| Evangelista, M | 1 |
| Bigard, MA | 2 |
| Gaucher, P | 2 |
| Miotti, T | 1 |
| Reichen, J | 2 |
| McLaren, MI | 1 |
| Taylor, I | 1 |
| Tandberg, D | 1 |
| Rector, WG | 1 |
| Ohara, N | 1 |
| Walker, S | 1 |
| Teltscher, U | 1 |
| Bode, JC | 1 |
| Bass, NM | 1 |
| Franco, D | 1 |
| Smadja, C | 1 |
| Buffet, C | 2 |
| Fritsch, J | 1 |
| Pelletier, G | 2 |
| Honein, K | 1 |
| Attali, P | 2 |
| Etienne, JP | 2 |
| Dembe, K | 1 |
| Stryjek-Kamińska, D | 1 |
| Alexandrino, PT | 1 |
| Alves, MM | 1 |
| Pinto Correia, J | 1 |
| Aubert, A | 1 |
| Lemman, M | 1 |
| Smythe, WR | 1 |
| Feinman, L | 1 |
| Salmon, RJ | 1 |
| Uzzan, J | 1 |
| Girodet, J | 1 |
| Gislon, J | 1 |
| Patris, A | 1 |
| Babb, RR | 1 |
| Mitchell, RL | 1 |
| McAlpine, LG | 1 |
| Hilditch, TE | 1 |
| Dagg, JH | 1 |
| Marbet, UA | 1 |
| Straumann, A | 1 |
| Gyr, KE | 1 |
| Beglinger, C | 1 |
| Schaub, N | 1 |
| Bögtlin, J | 1 |
| Loosli, J | 1 |
| Kiowski, W | 1 |
| Ritz, R | 1 |
| Stalder, GA | 1 |
| Pomier-Layrargues, G | 2 |
| Villeneuve, JP | 2 |
| Willems, B | 2 |
| Huet, PM | 2 |
| Marleau, D | 2 |
| Wiesner, RH | 1 |
| Valla, D | 1 |
| Gaudin, C | 1 |
| Geoffroy, P | 1 |
| Lee, SS | 1 |
| Duguay, L | 1 |
| Lapointe, R | 1 |
| Tanguay, S | 1 |
| Infante-Rivard, C | 1 |
| Lavoie, P | 1 |
| el-Hawy, A | 1 |
| el Nasr, MS | 1 |
| Hussein, T | 1 |
| el-Sayed, AA | 1 |
| Filippazzo, MG | 1 |
| Tinè, F | 1 |
| Morabito, A | 1 |
| Ferrari, A | 1 |
| Marenco, G | 1 |
| Cello, JP | 1 |
| Crass, RA | 1 |
| Grendell, JH | 1 |
| Trunkey, DD | 1 |
| Queuniet, AM | 1 |
| Czernichow, P | 1 |
| Lerebours, E | 1 |
| Ducrotte, P | 1 |
| Tranvouez, JL | 1 |
| Colin, R | 1 |
| Chamontin, B | 1 |
| Cassigneul, J | 1 |
| Scheurlen, M | 1 |
| Egberts, EH | 1 |
| Dölle, W | 1 |
| Chauvin, C | 1 |
| Verneau, A | 1 |
| Carretier, M | 1 |
| Bardet-Tassin, P | 1 |
| Lévy, VG | 1 |
| Servent, L | 1 |
| Okabe, S | 1 |
| Saziki, R | 1 |
| Takagi, K | 1 |
| Zhuk, EA | 1 |
| Meves, M | 1 |
| Meiisel, P | 1 |
| Katuranić, D | 1 |
| Todaro, RT | 1 |
| Meensook, C | 1 |
| Lecchi, RJ | 1 |
| Demeter, E | 1 |
| Rösch, J | 3 |
| Gray, RK | 1 |
| Grollman, JH | 1 |
| Ross, G | 1 |
| Steckel, RJ | 1 |
| Weiner, M | 1 |
| Dotter, CT | 2 |
| Rose, RW | 2 |
| Stark, RD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites[NCT02649335] | Phase 3 | 190 participants (Actual) | Interventional | 2015-07-01 | Completed | ||
| VICIS - Vienna Cirrhosis Study[NCT03267615] | 10,000 participants (Anticipated) | Observational [Patient Registry] | 2017-02-01 | Recruiting | |||
| Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Variceal Bleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis (PVT): A Multicenter Randomized Trial[NCT06122753] | 120 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | |||
| HVPG-guided Laparoscopic Versus Endoscopic Therapy for Variceal Rebleeding in Portal Hypertension: A Multicenter Randomized Controlled Trial (CHESS1803)[NCT03783065] | 40 participants (Anticipated) | Interventional | 2019-01-02 | Recruiting | |||
| Transjugular Intrahepatic Portosystemic Shunt Versus Endoscopic Treatment Combined With Propranolol for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis: A Randomized Controlled Trial[NCT01326949] | 52 participants (Actual) | Interventional | 2011-05-31 | Completed | |||
| A Prospective Multicenter Cohort Study on the Timing of Emergency Endoscopy for Esophagogastric Variceal Bleeding in Cirrhosis[NCT04932200] | 608 participants (Anticipated) | Observational | 2021-06-15 | Not yet recruiting | |||
| Timing of Endoscopic Intervention in Patients With Cirrhosis With Acute Variceal Upper Gastrointestinal Hemorrhage (TEACH Trial): a Randomized Clinical Trial[NCT04786743] | 400 participants (Anticipated) | Interventional | 2021-04-20 | Recruiting | |||
| A Novel Algorithm to Stratify Clinical Decompensation Risk in Patients With Compensated Advanced Chronic Liver Disease (CHESS2108)[NCT05100485] | 1,000 participants (Actual) | Observational | 2022-01-01 | Completed | |||
| Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension[NCT01059396] | Phase 4 | 201 participants (Actual) | Interventional | 2010-01-28 | Completed | ||
| CHESS-SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease: an International Multicenter Study (CHESS2102)[NCT04975477] | 1,000 participants (Anticipated) | Observational | 2021-07-16 | Not yet recruiting | |||
| Prevention of Progression of Portal Hypertension in Compensated Cirrhosis Using Selective Hepatic Vasodilators. A Double-blind, Multicenter,Randomized Controlled Trial[NCT01282398] | Phase 4 | 80 participants (Anticipated) | Interventional | 2011-04-30 | Not yet recruiting | ||
| Banding Ligation Plus Propranolol Versus Banding Ligation to Prevent Rebleeding of Esophageal Varices[NCT02740166] | Phase 4 | 212 participants (Anticipated) | Interventional | 2013-06-30 | Recruiting | ||
| Comparison of Endoscopic Variceal Ligation (EVL) and Propranolol in Secondary Prophylaxis of Variceal Bleeding in Patients With Non Cirrhotic Portal Hypertension (NCPH): A Prospective Randomized Controlled Trial[NCT01000779] | Phase 3 | 100 participants (Anticipated) | Interventional | 2005-01-31 | Completed | ||
| Endoscopic Cyanoacrylate Injection Versus Beta-Blockers for Secondary Prophylaxis of Gastric Variceal Bleed[NCT00888784] | 64 participants (Actual) | Interventional | 2006-08-31 | Completed | |||
| EUS-guided Combined Therapy of Coiling and 2-octyl-cyanoacrylate Injection With Beta Blocker Therapy Versus Beta Blocker Alone for the Primary Prophylaxis of GOV II and IGV I[NCT04075760] | 26 participants (Anticipated) | Interventional | 2019-08-01 | Recruiting | |||
| A Randomized Controlled Trial Comparing Cyanoacrylate Injection Versus Beta-Blockers Versus No Treatment for Primary Prophylaxis of Gastric Variceal Bleed[NCT00905996] | 74 participants (Actual) | Interventional | 2006-08-31 | Completed | |||
| Prospective Cohort Study to Evaluate Long-term Outcomes in Patients With Liver Cirrhosis of Boramae Hospital[NCT01943318] | 500 participants (Actual) | Observational [Patient Registry] | 2013-01-31 | Completed | |||
| Endoscopic and Microbiological Assessment of the Effect of Carvedilol Combined With Berberine on GOV in Cirrhosis: a Prospective Cohort Study[NCT04543643] | Phase 3 | 288 participants (Anticipated) | Interventional | 2021-11-01 | Not yet recruiting | ||
| Pilot Study to Evaluate the Correlation Between ¹³C Methacetin Breath Test (MBT) and HVPG Measurement as a Tool for Identifying Responders to Portal Hypertension Therapy[NCT01851252] | Phase 1 | 19 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Is Capsule Endoscopy Accurate and Cost-effective Enough to Screen Cirrhotic Patients for Varices & Other Lesions?[NCT01079416] | 65 participants (Actual) | Observational | 2006-06-30 | Completed | |||
| Propanolol for Primary Prophylaxis for Variceal Bleed in Biliary Atresia - An Open Label Randomized Controlled Study[NCT04494763] | 92 participants (Anticipated) | Interventional | 2020-08-15 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
57 reviews available for propranolol and Hematochezia
| Article | Year |
|---|---|
Exploration on the Effect of Nonselective
Topics: Adrenergic beta-Antagonists; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; He | 2022 |
Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension.
Topics: Adrenergic beta-Antagonists; Ascites; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal H | 2023 |
Diagnosis and Management of Cirrhosis and Its Complications: A Review.
Topics: Adult; Ascites; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hepatic Enc | 2023 |
Pharmacologic Management of Portal Hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Anticoagulants; Antihypertensi | 2019 |
Portal hypertension and its management in children.
Topics: Adrenergic beta-Antagonists; Child; Consensus; Endoscopy; Gastrointestinal Hemorrhage; Guidelines as | 2018 |
Pharmacologic prevention of variceal bleeding and rebleeding.
Topics: Adrenergic beta-Antagonists; Atorvastatin; Carbazoles; Carvedilol; Esophageal and Gastric Varices; G | 2018 |
[Management of compensated liver cirrhosis 2018 - Evidence based prophylactic measures].
Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Germany; Hepatic Encephalop | 2018 |
Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices.
Topics: Adrenergic beta-Antagonists; Adult; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hem | 2018 |
Management of gastric varices.
Topics: Anti-Bacterial Agents; Balloon Occlusion; Cardiovascular Agents; Cyanoacrylates; Esophageal and Gast | 2014 |
Combined therapies versus monotherapies for the first variceal bleeding in patients with high-risk varices: a meta-analysis of randomized controlled trials.
Topics: Combined Modality Therapy; Databases, Bibliographic; Drug Therapy, Combination; Endpoint Determinati | 2014 |
Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis.
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Esophageal and Ga | 2016 |
Beta-blockers in the prevention of gastrointestinal bleeding.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Clinical Trials as Topic; Esophageal and Gastr | 1990 |
beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Bacterial Infections; Bacterial Translocation; Databases, Bibliographic | 2009 |
Prognostic markers in patients who have recovered from an acute variceal bleeding: role of HVPG measurement.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Biomarkers; Esophageal and Gastric Varices; Ga | 2011 |
Pharmacotherapy alone vs endoscopic variceal ligation combination for secondary prevention of oesophageal variceal bleeding: meta-analysis.
Topics: Adrenergic beta-Antagonists; Combined Modality Therapy; Esophageal and Gastric Varices; Esophagoscop | 2012 |
Bleeding from ruptured oesophageal varices: propranolol for primary prevention.
Topics: Adrenergic beta-Antagonists; Combined Modality Therapy; Diuretics; Endoscopy; Esophageal and Gastric | 2012 |
Meta analysis of propranolol effects on gastrointestinal hemorrhage in cirrhotic patients.
Topics: Adrenergic beta-Antagonists; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Propranolol; Rand | 2003 |
Cirrhotic portal hypertension: current and future medical therapy for primary and secondary prevention of variceal bleeding.
Topics: Adrenergic beta-Antagonists; Animals; Contraindications; Drug Therapy, Combination; Endoscopy; Esoph | 2006 |
[The effect of propranolol on portal hypertension].
Topics: Adrenergic beta-Antagonists; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hy | 1992 |
Medical treatment of portal hypertension and oesophageal varices.
Topics: Blood Flow Velocity; Embolization, Therapeutic; Esophageal and Gastric Varices; Gastrointestinal Hem | 1983 |
Non-operative management of variceal bleeding.
Topics: Electrocoagulation; Embolization, Therapeutic; Esophageal and Gastric Varices; Gastrointestinal Hemo | 1984 |
Management of upper gastrointestinal haemorrhage.
Topics: Adult; Aged; Combined Modality Therapy; Embolization, Therapeutic; Esophageal and Gastric Varices; E | 1983 |
Theoretical and practical considerations in the treatment of portal hypertension secondary to hepatic cirrhosis.
Topics: Animals; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; | 1984 |
Oesophageal varices prior to bleeding. Diagnosis and physiological and therapeutic effects of propranolol in cirrhosis.
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hemodynamics; Humans; Liver Cirrhosis; | 1993 |
Drug treatment of esophageal variceal bleeding: alternative or supplement to endoscopic therapy?
Topics: Adrenergic beta-Antagonists; Combined Modality Therapy; Esophageal and Gastric Varices; Esophagoscop | 1995 |
Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis.
Topics: Adult; Female; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Male; Middle Aged; Propranolol; | 1997 |
[Gastropathy due to portal hypertension].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Diagnosis, Differential; Gastritis | 1997 |
Beta-blockers for prophylaxis of bleeding from esophageal varices in cirrhotic portal hypertension. Review of the literature.
Topics: Adrenergic beta-Antagonists; Combined Modality Therapy; Esophageal and Gastric Varices; Gastrointest | 1996 |
Portal-hypertensive gastropathy.
Topics: Esophageal and Gastric Varices; Gastric Acid; Gastric Mucosa; Gastrointestinal Hemorrhage; Humans; H | 1998 |
The sixth Carlos E. Rubio Memorial Lecture. Prevention and treatment of variceal hemorrhage.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination | 2000 |
Pharmacologic therapy for portal hypertension.
Topics: Acute Disease; Adrenergic beta-Antagonists; Endoscopy, Gastrointestinal; Gastrointestinal Agents; Ga | 2001 |
Portal hypertension in schistosomiasis: pathophysiology and treatment.
Topics: Animals; Cricetinae; Esophageal and Gastric Varices; Follow-Up Studies; Gastrointestinal Hemorrhage; | 1992 |
Prevention of first variceal bleeding: new prospects.
Topics: Adrenergic beta-Antagonists; Clinical Trials as Topic; Esophageal and Gastric Varices; Gastrointesti | 1992 |
Balloon tamponade and vasoactive drugs in the control of acute variceal haemorrhage.
Topics: Antihypertensive Agents; Balloon Occlusion; Catheterization; Esophageal and Gastric Varices; Gastroi | 1992 |
Portal hypertensive gastropathy.
Topics: Animals; Diagnosis, Differential; Esophageal and Gastric Varices; Gastric Mucosa; Gastritis; Gastroi | 1992 |
Beta-adrenergic antagonists for primary prevention of gastrointestinal hemorrhage in patients with cirrhosis and esophageal varices.
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Nadolol; Propr | 1992 |
Propranolol in variceal hemorrhage.
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Propranol | 1992 |
Bleeding esophagogastric varices. Ways to treat active episodes and prevent recurrence.
Topics: Balloon Occlusion; Catheterization; Clinical Protocols; Education, Medical, Continuing; Endoscopy, G | 1991 |
Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter
Topics: Adrenergic beta-Antagonists; Ascites; Esophageal and Gastric Varices; Female; Gastrointestinal Hemor | 1991 |
[Beta-adrenergic antagonists and endoscopic sclerotherapy for the prevention of digestive hemorrhage].
Topics: Adrenergic beta-Antagonists; Combined Modality Therapy; Endoscopy, Gastrointestinal; Gastrointestina | 1991 |
Portal hypertensive gastropathy.
Topics: Animals; Gastric Mucosa; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Liver Cirrhosis; | 1991 |
[Chemotherapy of portal hypertension].
Topics: Antihypertensive Agents; Drug Evaluation; Esophageal and Gastric Varices; Gastrointestinal Hemorrhag | 1991 |
Meta-analysis of value of propranolol in prevention of variceal haemorrhage.
Topics: Adrenergic beta-Antagonists; Chi-Square Distribution; Drug Evaluation; Esophageal and Gastric Varice | 1990 |
[Primary prevention of digestive hemorrhages in cirrhotic patients].
Topics: Adrenergic beta-Antagonists; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Li | 1990 |
[Treatment of hemorrhage of esophageal varices].
Topics: Balloon Occlusion; Catheterization; Combined Modality Therapy; Esophageal and Gastric Varices; Gastr | 1990 |
Prevention of recurrent variceal hemorrhage: to block or not to block?
Topics: Atenolol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Prop | 1990 |
[Beta blockaders and portal hypertension].
Topics: Adrenergic beta-Antagonists; Animals; Gastrointestinal Hemorrhage; Hemodynamics; Humans; Hypertensio | 1989 |
[Pharmacological therapy of portal hypertension].
Topics: Acute Disease; Adrenergic beta-Antagonists; Chronic Disease; Clinical Trials as Topic; Esophageal an | 1985 |
Advances in managing variceal bleeding in portal hypertension.
Topics: Catheterization; Embolization, Therapeutic; Esophageal and Gastric Varices; Gastrointestinal Hemorrh | 1986 |
Emergency management of upper gastrointestinal hemorrhage.
Topics: Aged; Angiography; Antacids; Blood Cell Count; Blood Chemical Analysis; Blood Transfusion; Emergency | 1986 |
Drug therapy for portal hypertension.
Topics: Animals; Clinical Trials as Topic; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hemo | 1986 |
Pharmacological therapy of portal hypertension.
Topics: Acute Disease; Endoscopy; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hypertension, | 1986 |
[Current views on non-invasive treatment of hemorrhaging esophageal varices].
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hemostatic Techniques; Humans; Proprano | 1988 |
[Sclerotherapy of esophageal varices using ethanol in combination with propranolol: clinical study of 30 patients].
Topics: Aged; Drug Therapy, Combination; Esophageal and Gastric Varices; Ethanol; Female; Gastrointestinal H | 1988 |
The medical prevention of variceal bleeding.
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Propranol | 1988 |
Management of the patient with hemorrhaging esophageal varices.
Topics: Airway Obstruction; Catheterization; Esophageal and Gastric Varices; Fluid Therapy; Gastrointestinal | 1986 |
Ideal treatment of portal hypertension in 1985.
Topics: Acute Disease; Clinical Trials as Topic; Double-Blind Method; Endoscopy; Esophageal and Gastric Vari | 1985 |
128 trials available for propranolol and Hematochezia
| Article | Year |
|---|---|
Propranolol vs. band ligation for primary prophylaxis of variceal hemorrhage in cirrhotic patients with ascites: a randomized controlled trial.
Topics: Acute Kidney Injury; Ascites; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; L | 2022 |
5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial.
Topics: Adrenergic beta-Antagonists; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hy | 2023 |
Comparison of carvedilol and propranolol for primary prophylaxis of esophageal variceal bleed in cirrhotic patients.
Topics: Adrenergic beta-Antagonists; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage | 2023 |
Small-Diameter Transjugular Intrahepatic Portosystemic Shunt versus Endoscopic Variceal Ligation Plus Propranolol for Variceal Rebleeding in Advanced Cirrhosis.
Topics: Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Male; | 2023 |
Hepatic venous pressure gradient-guided laparoscopic splenectomy and pericardial devascularisation versus endoscopic therapy for secondary prophylaxis for variceal rebleeding in portal hypertension (CHESS1803): study protocol of a multicenter randomised c
Topics: China; Combined Modality Therapy; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Human | 2020 |
Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial.
Topics: Adult; Combined Modality Therapy; Esophageal and Gastric Varices; Female; Follow-Up Studies; Gastroi | 2018 |
Efficacy of carvedilol versus propranolol versus variceal band ligation for primary prevention of variceal bleeding.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Egypt; Esophageal and Gastric Vari | 2018 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
Effects of propranolol or propranolol plus isosorbide-5-mononitrate on variceal pressure in schistosomiasis.
Topics: Adult; China; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Gastrointestinal He | 2013 |
Propranolol associated with endoscopic band ligation reduces recurrence of esophageal varices for primary prophylaxis of variceal bleeding: a randomized-controlled trial.
Topics: Adrenergic beta-Antagonists; Adult; Combined Modality Therapy; Endoscopy, Gastrointestinal; Esophage | 2015 |
Prevention of Rebleeding From Esophageal Varices in Patients With Cirrhosis Receiving Small-Diameter Stents Versus Hemodynamically Controlled Medical Therapy.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Gast | 2015 |
A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis.
Topics: Adult; Antihypertensive Agents; Ascites; Carbazoles; Carvedilol; End Stage Liver Disease; Esophageal | 2016 |
Carvedilol versus propranolol effect on hepatic venous pressure gradient at 1 month in patients with index variceal bleed: RCT.
Topics: Adult; Antihypertensive Agents; Carbazoles; Carvedilol; Esophageal and Gastric Varices; Esophagoscop | 2017 |
Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding.
Topics: Adrenergic beta-Antagonists; Aged; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrha | 2009 |
Propranolol, isosorbide mononitrate and endoscopic band ligation - alone or in varying combinations for the prevention of esophageal variceal rebleeding.
Topics: Adult; Aged; Combined Modality Therapy; Endoscopy; Esophageal and Gastric Varices; Gastrointestinal | 2009 |
Addition of propranolol and isosorbide mononitrate to endoscopic variceal ligation does not reduce variceal rebleeding incidence.
Topics: Adult; Combined Modality Therapy; Endoscopy, Digestive System; Esophageal and Gastric Varices; Femal | 2009 |
Equal efficacy of endoscopic variceal ligation and propranolol in preventing variceal bleeding in patients with noncirrhotic portal hypertension.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Child; Child, Preschool; Esophageal and Gastric Vari | 2010 |
Endoscopic cyanoacrylate injection versus beta-blocker for secondary prophylaxis of gastric variceal bleed: a randomised controlled trial.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Child; Cyanoacrylates; Embolization, Therapeut | 2010 |
Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers: a randomized controlled trial.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Child; Cyanoacrylates; Esophageal and Gastric | 2011 |
Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers: a randomized controlled trial.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Child; Cyanoacrylates; Esophageal and Gastric | 2011 |
Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers: a randomized controlled trial.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Child; Cyanoacrylates; Esophageal and Gastric | 2011 |
Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers: a randomized controlled trial.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Child; Cyanoacrylates; Esophageal and Gastric | 2011 |
[Comparison of endoscopic band ligation and propranolol for the primary prophylaxis of variceal bleeding in cirrhosis].
Topics: Aged; Endoscopy, Gastrointestinal; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrha | 2012 |
Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; | 2013 |
Primary prophylaxis of variceal hemorrhage: a randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate.
Topics: Antihypertensive Agents; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Gastroin | 2002 |
"A La Carte" treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleeding.
Topics: Adult; Female; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Isosorbide Dinitrate; Male | 2002 |
[The randomized controlled trial of isosorbide mononitrate plus propranolol compared with propranolol alone for the prevention of variceal rebleeding].
Topics: Adult; Dizziness; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Headache; Humans; | 2002 |
Long term effects of propranolol on portal pressure in cirrhotic patients.
Topics: Antihypertensive Agents; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hemody | 2003 |
Endoscopic histoacryl obliteration vs. propranolol in the prevention of esophagogastric variceal rebleeding: a randomized trial.
Topics: Adult; Aged; Antihypertensive Agents; Enbucrilate; Endoscopy; Esophageal and Gastric Varices; Female | 2003 |
Cirrhosis and bleeding: the need for very early management.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Ascites; Double-Blind Method; Esophageal and Gastric Varic | 2003 |
Effect of propranolol and depot lanreotide SR on postprandial and circadian portal haemodynamics in cirrhosis.
Topics: Antihypertensive Agents; Circadian Rhythm; Delayed-Action Preparations; Esophageal and Gastric Varic | 2003 |
Propranolol alone may not be acceptable to prevent first esophageal variceal bleeding in Japanese cirrhotic patients: randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hu | 2004 |
Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis.
Topics: Actuarial Analysis; Adrenergic beta-Antagonists; Esophageal and Gastric Varices; Esophagus; Female; | 2004 |
Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding.
Topics: Adrenergic beta-Antagonists; Adult; Cause of Death; Combined Modality Therapy; Esophageal and Gastri | 2005 |
Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices.
Topics: Adrenergic beta-Antagonists; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hu | 2005 |
Variceal band ligation versus propranolol for primary prophylaxis of variceal bleeding in cirrhosis.
Topics: Adrenergic beta-Antagonists; Esophageal and Gastric Varices; Follow-Up Studies; Gastrointestinal Hem | 2005 |
Evaluation of endoscopic variceal ligation (EVL) versus propanolol plus isosorbide mononitrate/nadolol (ISMN) in the prevention of variceal rebleeding: comparison of cirrhotic and noncirrhotic patients.
Topics: Adult; Antihypertensive Agents; Drug Therapy, Combination; Endoscopy, Digestive System; Esophageal a | 2005 |
Endoscopic variceal ligation vs. propranolol for prevention of first variceal bleeding: a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Aged; Cause of Death; Epidemiologic Methods; Esophageal and Gastric Var | 2005 |
Endoscopic variceal ligation versus propranolol in prophylaxis of first variceal bleeding in patients with cirrhosis.
Topics: Adrenergic beta-Antagonists; Endoscopy, Gastrointestinal; Esophageal and Gastric Varices; Female; Fo | 2006 |
A randomized study comparing ligation with propranolol for primary prophylaxis of variceal bleeding in candidates for liver transplantation.
Topics: Adrenergic beta-Antagonists; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Ligation; Liver | 2007 |
Hemodynamic effects of propranolol with spironolactone in patients with variceal bleeds: a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Adult; Diuretics; Drug Therapy, Combination; Esophageal and Gastric Var | 2008 |
Propranolol--a medical treatment for portal hypertension?
Topics: Administration, Oral; Cardiac Output; Clinical Trials as Topic; Esophageal and Gastric Varices; Gast | 1980 |
[Beta blocker prevention of hemorrhages from esophageal varices in liver cirrhosis].
Topics: Adrenergic beta-Antagonists; Blood Pressure; Clinical Trials as Topic; Esophageal and Gastric Varice | 1983 |
Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis.
Topics: Adult; Aged; Clinical Trials as Topic; Esophageal and Gastric Varices; Female; Gastrointestinal Hemo | 1983 |
What to do about esophageal varices?
Topics: Clinical Trials as Topic; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Propr | 1983 |
Propranolol and haemorrhage due to rupture of oesophageal varices.
Topics: Clinical Trials as Topic; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hyper | 1984 |
Treatment of bleeding varices: controversy and opportunity.
Topics: Clinical Trials as Topic; Embolization, Therapeutic; Esophageal and Gastric Varices; Gastrointestina | 1984 |
Gastrointestinal bleeding after abrupt cessation of propranolol administration in cirrhosis.
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Propranolol; S | 1982 |
Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study.
Topics: Administration, Oral; Adult; Aged; Clinical Trials as Topic; Esophageal and Gastric Varices; Female; | 1981 |
Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Esophageal and Gastric Varices; Gastrointestinal | 1995 |
Effects of propranolol on gastric mucosal perfusion and serum gastrin level in cirrhotic patients with portal hypertensive gastropathy.
Topics: Double-Blind Method; Female; Gastric Mucosa; Gastrins; Gastrointestinal Hemorrhage; Humans; Hyperten | 1994 |
Propranolol reduces mortality in patients with portal hypertension secondary to schistosomiasis.
Topics: Adult; Double-Blind Method; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hum | 1994 |
Has propranolol rendered sclerotherapy obsolete for poor risk alcoholic cirrhotic patients?
Topics: Combined Modality Therapy; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis, | 1994 |
Duplex Doppler ultrasonographic comparison of the effects of propranolol and isosorbide-5-mononitrate on portal hemodynamics.
Topics: Delayed-Action Preparations; Double-Blind Method; Drug Monitoring; Esophageal and Gastric Varices; F | 1993 |
Effect of propranolol on prevention of first variceal bleed and survival in patients with chronic liver disease.
Topics: Adult; Aged; Child; Child, Preschool; Chronic Disease; Double-Blind Method; Esophageal and Gastric V | 1994 |
Propranolol versus sclerotherapy in preventing variceal rebleeding: a randomized controlled trial.
Topics: Aged; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged | 1993 |
Reduction of variceal pressure by propranolol: comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis.
Topics: Adult; Aged; Azygos Vein; Double-Blind Method; Esophageal and Gastric Varices; Female; Gastrointesti | 1993 |
Propranolol in the prevention of recurrent upper gastrointestinal bleeding in patients with cirrhosis undergoing endoscopic sclerotherapy. A randomized controlled trial.
Topics: Aged; Combined Modality Therapy; Endoscopy; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; | 1993 |
[Prevention of digestive hemorrhage recurrence in hepatic cirrhosis with propranolol. A 4 years' follow-up study].
Topics: Adult; Aged; Aged, 80 and over; Esophageal and Gastric Varices; Female; Follow-Up Studies; Gastroint | 1993 |
[Propranolol for prophylaxis of first hemorrhage in cirrhotic patients with esophageal varices--a controlled study comparing with sclerotherapy].
Topics: Aged; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; | 1993 |
Isosorbide-5-mononitrate versus propranolol in the prevention of first bleeding in cirrhosis.
Topics: Aged; Digestive System; Endoscopy; Female; Gastrointestinal Hemorrhage; Humans; Isosorbide Dinitrate | 1993 |
Effects of propranolol compared with clonidine on portal haemodynamics: a double-blind cross-over study using duplex-Doppler ultrasonography.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Blood Flow Velocity; Blood Pressure; Clonidine; Cro | 1995 |
The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Ascites; Atrial Natriuretic Factor; | 1996 |
Sclerotherapy versus sclerotherapy and propranolol in the prevention of rebleeding from oesophageal varices: a randomised study.
Topics: Adult; Aged; Antihypertensive Agents; Combined Modality Therapy; Esophageal and Gastric Varices; Fem | 1996 |
Measurement of variceal pressure with an endoscopic pressure sensitive gauge: validation and effect of propranolol therapy in chronic conditions.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Double-Blind Method; Endoscopy; Esophageal and Gastric Var | 1996 |
Non-invasive variceal pressure measurements: validation and clinical implications.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure Determination; Double-Blind Method; Esophageal | 1996 |
Prevention of recurrent esophageal bleeding and survival in patients with alcoholic cirrhosis: a randomized study.
Topics: Adult; Aged; Antihypertensive Agents; Esophageal and Gastric Varices; Female; Gastrointestinal Hemor | 1996 |
Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Embolization, Therapeutic; Endoscopy; Eso | 1997 |
Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding.
Topics: Adult; Aged; Esophageal and Gastric Varices; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; | 1997 |
Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Hu | 1997 |
Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding.
Topics: Adrenergic beta-Antagonists; Adult; Endoscopy; Esophageal and Gastric Varices; Female; Gastrointesti | 1999 |
Endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleed: preliminary report of a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Adult; Esophageal and Gastric Varices; Female; Follow-Up Studies; Gastr | 1999 |
Propranolol in prevention of portal hypertensive hemorrhage in children: a pilot study.
Topics: Adolescent; Antihypertensive Agents; Child; Child, Preschool; Esophageal and Gastric Varices; Female | 1999 |
[Primary prevention of esophageal variceal rupture: endoscopic ligation or propranolol?].
Topics: Adrenergic beta-Antagonists; Adult; Endoscopy, Digestive System; Esophageal and Gastric Varices; Fol | 1999 |
Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding.
Topics: Adrenergic beta-Antagonists; Aged; Drug Synergism; Drug Therapy, Combination; Esophageal and Gastric | 2000 |
Endoscopic sclerotherapy plus propranolol versus propranolol alone in the primary prevention of bleeding in high risk cirrhotic patients with esophageal varices: a prospective multicenter randomized trial.
Topics: Adrenergic beta-Antagonists; Esophageal and Gastric Varices; Esophagoscopy; Female; Follow-Up Studie | 2000 |
[A randomized controlled study of ligustrazine in combination with propranolol for prevention of recurrent esophageal varices bleeding].
Topics: Adult; Aged; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Gastrointestinal Hem | 2000 |
Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding.
Topics: Adrenergic beta-Antagonists; Esophageal and Gastric Varices; Esophagoscopy; Follow-Up Studies; Gastr | 2000 |
Daily variation of azygos and portal blood flow and the effect of propranolol administration once an evening in cirrhotics.
Topics: Adrenergic beta-Antagonists; Aged; Azygos Vein; Esophageal and Gastric Varices; Female; Gastrointest | 2001 |
The effects of endoscopic variceal ligation and propranolol on portal hypertensive gastropathy: a prospective, controlled trial.
Topics: Adult; Aged; Combined Modality Therapy; Endoscopy, Gastrointestinal; Esophageal and Gastric Varices; | 2001 |
Propranolol for the prevention of first esophageal variceal hemorrhage: a lifetime commitment?
Topics: Adrenergic beta-Antagonists; Double-Blind Method; Drug Administration Schedule; Esophageal and Gastr | 2001 |
Should neither sclerotherapy nor propranolol be used prophylactically for oesophageal varices?
Topics: Combined Modality Therapy; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Live | 1992 |
Does elective sclerotherapy improve the efficacy of long-term propranolol for prevention of recurrent bleeding in patients with severe cirrhosis? A prospective multicenter, randomized trial.
Topics: Esophageal Diseases; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Liv | 1992 |
Endoscopic sclerotherapy versus propranolol in prevention of recurrent variceal bleeding in patients with child's B and C cirrhosis: a preliminary report.
Topics: Adult; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; | 1992 |
Beta-blockers and prevention of first variceal hemorrhage: tantalizing expectations?
Topics: Double-Blind Method; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Humans; Ma | 1992 |
Factors associated with failure of propranolol for the prevention of first bleeding in cirrhotic patients. The Study Group of Primary Prophylaxis.
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Incidence; Liver Cirrhosis; Liv | 1992 |
Propranolol reduces the rebleeding rate during endoscopic sclerotherapy before variceal obliteration.
Topics: Adult; Aged; Esophageal and Gastric Varices; Esophagoscopy; Female; Gastrointestinal Hemorrhage; Hum | 1992 |
Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter
Topics: Adrenergic beta-Antagonists; Ascites; Esophageal and Gastric Varices; Female; Gastrointestinal Hemor | 1991 |
Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis.
Topics: Actuarial Analysis; Acute Disease; Drug Administration Schedule; Drug Evaluation; Female; Follow-Up | 1991 |
[Prevention of recurrent hemorrhage in patients with cirrhosis. Results of a controlled trial of propranolol versus endoscopic sclerotherapy].
Topics: Actuarial Analysis; Adult; Endoscopy, Gastrointestinal; Esophageal and Gastric Varices; Female; Foll | 1991 |
[Prospective controlled study of elective sclerotherapy plus oral propranolol for prevention of recurrent bleeding in cirrhotics with recent variceal hemorrhage].
Topics: Administration, Oral; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hepatic Veins; Hu | 1991 |
Prevention of recurrent variceal bleeding in alcoholic cirrhotic patients: prospective controlled trial of propranolol and sclerotherapy.
Topics: Combined Modality Therapy; Esophageal and Gastric Varices; Follow-Up Studies; Gastrointestinal Hemor | 1991 |
Prophylaxis of first hemorrhage from esophageal varices by sclerotherapy, propranolol or both in cirrhotic patients: a randomized multicenter trial. The PROVA Study Group.
Topics: Esophageal and Gastric Varices; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Inci | 1991 |
[Primary prevention of digestive hemorrhages in cirrhotic patients].
Topics: Adrenergic beta-Antagonists; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Li | 1990 |
Prophylaxis for variceal bleeding.
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Propranolol; S | 1991 |
Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial. The Boston-New Haven-Barcelona Portal Hypertension Study Group.
Topics: Blood Pressure; Double-Blind Method; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorr | 1991 |
A controlled trial of oral propranolol compared with injection sclerotherapy for the long-term management of variceal bleeding.
Topics: Administration, Oral; Blood Pressure; Clinical Trials as Topic; Esophageal and Gastric Varices; Fema | 1990 |
Prevention of recurrent variceal hemorrhage: to block or not to block?
Topics: Atenolol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Prop | 1990 |
Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage.
Topics: Adult; Aged; Blood Pressure; Double-Blind Method; Esophageal and Gastric Varices; Female; Gastrointe | 1990 |
Preventive therapy of first gastrointestinal bleeding in patients with cirrhosis: results of a controlled trial comparing propranolol, endoscopic sclerotherapy and placebo.
Topics: Esophageal and Gastric Varices; Esophagoscopy; Female; Follow-Up Studies; Gastrointestinal Hemorrhag | 1990 |
Evaluation of propranolol for prevention of recurrent bleeding from esophageal varices between sclerotherapy sessions.
Topics: Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Prop | 1990 |
Efficacy of oral propranolol and injection sclerotherapy in the long-term management of variceal bleeding.
Topics: Administration, Oral; Adult; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hu | 1990 |
Propranolol may prevent recurrence of oesophageal varices after obliteration by endoscopic sclerotherapy.
Topics: Adult; Aged; Combined Modality Therapy; Double-Blind Method; Esophageal and Gastric Varices; Esophag | 1990 |
Propranolol in the prevention of recurrent variceal hemorrhage in cirrhotic patients. A controlled trial.
Topics: Double-Blind Method; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Humans; Li | 1990 |
Controlled trial of propranolol to prevent recurrent variceal bleeding in patients with non-cirrhotic portal fibrosis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Clinical Trials as Topic; Esophageal and Gastric Vari | 1989 |
[Prevention of recurrent hemorrhage caused by the rupture of esophageal varices in cirrhotic patients. A controlled study of propranolol and clip ligation of the esophagus].
Topics: Adult; Aged; Clinical Trials as Topic; Esophageal and Gastric Varices; Esophagus; Female; Gastrointe | 1989 |
Beta-blockade prevents recurrent gastrointestinal bleeding in well-compensated patients with alcoholic cirrhosis: a multicenter randomized controlled trial.
Topics: Actuarial Analysis; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Atenolol; Clinical Trials a | 1989 |
Beta-blockers in the secondary prevention of gastrointestinal haemorrhage in well-compensated cirrhotics. A multicentre randomised controlled study.
Topics: Adrenergic beta-Antagonists; Atenolol; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Human | 1989 |
Randomized controlled study of propranolol for prevention of recurrent esophageal varices bleeding in patients with cirrhosis.
Topics: Adult; Clinical Trials as Topic; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage | 1989 |
Propranolol in prevention of rebleeding from oesophageal varices during the course of endoscopic sclerotherapy.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Esophageal and Gastric Varices; Esophago | 1989 |
Propranolol prevents first gastrointestinal bleeding in non-ascitic cirrhotic patients. Final report of a multicenter randomized trial. The Italian Multicenter Project for Propranolol in Prevention of Bleeding.
Topics: Adolescent; Adult; Aged; Ascites; Clinical Trials as Topic; Female; Follow-Up Studies; Gastrointesti | 1989 |
A randomised controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis.
Topics: Adult; Female; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Male; Propranolol; Randomized C | 1989 |
A randomised controlled trial of propranolol for the prevention of initial bleeding in cirrhotic patients with portal hypertension. Preliminary results. The Italian Multicenter Project for Propranolol in the Prevention of Bleeding.
Topics: Aged; Female; Gastrointestinal Hemorrhage; Hepatitis B Surface Antigens; Humans; Hypertension, Porta | 1989 |
Propranolol in the primary prevention of upper gastrointestinal tract haemorrhage in patients with cirrhosis of the liver and oesophageal varices.
Topics: Aged; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; | 1989 |
[Propranolol in the prevention of digestive bleeding in cirrhotic patients].
Topics: Blood Pressure; Cardiac Output; Clinical Trials as Topic; Esophageal and Gastric Varices; Female; Ga | 1989 |
Comparison of three nonsurgical treatments for bleeding esophageal varices.
Topics: Blood Transfusion; Combined Modality Therapy; Esophageal and Gastric Varices; Esophagoscopy; Ethanol | 1989 |
Comparison of treatments of bleeding varices: effects of differences between treatment intended and treatment received.
Topics: Combined Modality Therapy; Esophageal and Gastric Varices; Esophagoscopy; Gastrointestinal Hemorrhag | 1989 |
Comparison of propranolol with injection sclerotherapy in prevention of rebleeding from oesophageal varices in cirrhotic patients.
Topics: Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Male; | 1989 |
Sclerotherapy versus propranolol after first variceal haemorrhage in alcoholic cirrhosis.
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis, Alcoholic; Pro | 1985 |
[Pharmacological therapy of portal hypertension].
Topics: Acute Disease; Adrenergic beta-Antagonists; Chronic Disease; Clinical Trials as Topic; Esophageal an | 1985 |
Drug therapy for portal hypertension.
Topics: Animals; Clinical Trials as Topic; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hemo | 1986 |
[Beta-receptor blockaders in the prevention of hemorrhaging of esophageal varices?].
Topics: Adrenergic beta-Antagonists; Clinical Trials as Topic; Drug Evaluation; Esophageal and Gastric Varic | 1987 |
Propranolol or endoscopic sclerotherapy in the prevention of recurrence of variceal bleeding. A prospective, randomized controlled trial.
Topics: Adult; Clinical Trials as Topic; Endoscopy; Esophageal and Gastric Varices; Female; Follow-Up Studie | 1988 |
Prediction of variceal hemorrhage: a prospective study.
Topics: Combined Modality Therapy; Esophageal and Gastric Varices; Esophagoscopy; Gastrointestinal Hemorrhag | 1988 |
[Endoscopic sclerotherapy versus propranolol after hemorrhage caused by rupture of esophageal varices in patients with cirrhosis. Results of a 4-year randomized study].
Topics: Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Male; | 1988 |
Reduction in early recurrence of variceal bleeding by propranolol.
Topics: Acute Disease; Adult; Aged; Clinical Trials as Topic; Esophageal and Gastric Varices; Female; Gastro | 1988 |
Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices.
Topics: Clinical Trials as Topic; Esophageal and Gastric Varices; Female; Follow-Up Studies; Gastrointestina | 1987 |
Systemic and hepatic hemodynamics after variceal hemorrhage: effects of propranolol and placebo.
Topics: Adult; Aged; Clinical Trials as Topic; Esophageal and Gastric Varices; Female; Gastrointestinal Hemo | 1987 |
A randomized clinical trial of propranolol for the prevention of initial bleeding in cirrhosis with portal hypertension.
Topics: Clinical Trials as Topic; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Liver Cirrhosis | 1986 |
[Controlled study of propranolol in the prevention of recurrent hemorrhage in cirrhotic patients].
Topics: Adult; Aged; Clinical Trials as Topic; Esophageal and Gastric Varices; Follow-Up Studies; Gastrointe | 1987 |
Ideal treatment of portal hypertension in 1985.
Topics: Acute Disease; Clinical Trials as Topic; Double-Blind Method; Endoscopy; Esophageal and Gastric Vari | 1985 |
147 other studies available for propranolol and Hematochezia
| Article | Year |
|---|---|
Carvedilol as secondary prophylaxis for variceal bleeding in hepatosplenic schistosomiasis.
Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Ligation; Propranol | 2022 |
Blunted cardiovascular effects of beta-blockers in patients with cirrhosis: Relation to severity?
Topics: Adrenergic beta-Antagonists; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Li | 2022 |
Acute hemodynamic response to propranolol predicts bleeding and nonbleeding decompensation in patients with cirrhosis.
Topics: Adult; Aged; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hemodynamics; Humans; Live | 2022 |
Carvedilol Achieves Higher Hemodynamic Response and Lower Rebleeding Rates Than Propranolol in Secondary Prophylaxis.
Topics: Adrenergic beta-Antagonists; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage | 2023 |
Selumetinib for Refractory Pulmonary and Gastrointestinal Bleeding in Noonan Syndrome.
Topics: Benzimidazoles; Dipyridamole; Gastrointestinal Hemorrhage; Humans; Interferon-alpha; Male; Mitogen-A | 2022 |
KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications.
Topics: Adrenergic beta-Antagonists; Ammonia; Anti-Bacterial Agents; Carvedilol; Disaccharides; Endoscopy, G | 2020 |
Propranolol plus endoscopic ligation for variceal bleeding in patients with significant ascites: Propensity score matching analysis.
Topics: Adrenergic beta-Antagonists; Ascites; Combined Modality Therapy; Endoscopy; Esophageal and Gastric V | 2020 |
The Effect of Liraglutide on β-Blockade for Preventing Variceal Bleeding: A Case Series.
Topics: Adrenergic beta-Antagonists; Aged; Diabetes Mellitus, Type 2; Drug Interactions; Esophageal and Gast | 2020 |
Diagnosis and management of extrahepatic oesophageal variceal bleed in children in a low resourced setting.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Esophageal and Gastric Varices; Female; | 2020 |
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).
Topics: Austria; Carbazoles; Carvedilol; Comorbidity; Early Medical Intervention; Esophageal and Gastric Var | 2017 |
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).
Topics: Austria; Carbazoles; Carvedilol; Comorbidity; Early Medical Intervention; Esophageal and Gastric Var | 2017 |
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).
Topics: Austria; Carbazoles; Carvedilol; Comorbidity; Early Medical Intervention; Esophageal and Gastric Var | 2017 |
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).
Topics: Austria; Carbazoles; Carvedilol; Comorbidity; Early Medical Intervention; Esophageal and Gastric Var | 2017 |
Propranolol for gastrointestinal bleeding in two patients with continuous flow left ventricle assist device.
Topics: Anemia; Female; Gastrointestinal Hemorrhage; Heart Failure; Heart-Assist Devices; Humans; Male; Midd | 2018 |
Primary prophylaxis of variceal bleeding.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Endoscopy; Esophageal and Gastric Varices; Gast | 2018 |
Pregnancy in a patient with portal hypertension secondary to liver cirrhosis.
Topics: Adult; Antihypertensive Agents; Cardiotocography; Esophageal and Gastric Varices; Female; Gastrointe | 2018 |
Dose-dependent effect of propranolol on the hemodynamic response in cirrhotic patients with gastroesophageal varices.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Databases, Factual; Dose-Response Relationship, Drug; Esop | 2019 |
Recurrent bloody stools associated with visceral infantile haemangioma in a preterm twin girl.
Topics: Adrenergic beta-Antagonists; Diagnosis, Differential; Female; Gastrointestinal Hemorrhage; Hemangiom | 2018 |
Transjugular intrahepatic portosystemic shunt prevents rebleeding in cirrhotic patients having cavernous transformation of the portal vein without improving their survival.
Topics: Adult; Aged; Antihypertensive Agents; Esophageal and Gastric Varices; Female; Follow-Up Studies; Gas | 2019 |
Liver volume index predicts the risk of esophageal variceal hemorrhage in cirrhotic patients on propranolol prophylaxis.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Decision Support Techniques; Esophageal and Gastric Varice | 2019 |
The secondary prophylactic efficacy of beta-blocker after endoscopic gastric variceal obturation for first acute episode of gastric variceal bleeding.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Enbucrilate; Endoscopy, Digestive System; Esophageal and G | 2013 |
A complication to be aware of: hyperkalaemia following propranolol therapy for an infant with intestinal haemangiomatozis.
Topics: Albuterol; Angiography; Biopsy, Needle; Drug Therapy, Combination; Fluid Therapy; Follow-Up Studies; | 2014 |
The comparison of esophageal variceal ligation plus propranolol versus propranolol alone for the primary prophylaxis of esophageal variceal bleeding.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Esophageal and Gastric Varices; Female; Follow-Up Studies; | 2014 |
Extrahepatic portal vein obstruction in Egyptian children.
Topics: Child; Child, Preschool; Cohort Studies; Diagnosis, Differential; Egypt; Esophageal and Gastric Vari | 2015 |
[Kasabach-Merritt phenomenon (KMP) exacerbated by platelet transfusions].
Topics: Aspirin; Axilla; Combined Modality Therapy; Compression Bandages; Disease Progression; Disseminated | 2015 |
β-2 Adrenergic receptor gene polymorphism and response to propranolol in cirrhosis.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Case-Control Studies; Esophageal and Gastric V | 2015 |
Hepatic Hemangioma with Kasabach-Merritt Syndrome in an Adult Patient.
Topics: Abdomen; Ecchymosis; Female; Gastrointestinal Hemorrhage; Hemangioma; Humans; Kasabach-Merritt Syndr | 2016 |
Second prophylaxis of variceal bleeding in cirrhotic patients with a high HVPG.
Topics: Adult; Aged; China; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hepatic Enc | 2016 |
Risk and Predictors of Variceal Bleeding in Cirrhosis Patients Receiving Primary Prophylaxis With Non-Selective Beta-Blockers.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Ascites; Cohort Studies; Comorbidity; Dose-Response | 2016 |
Secondary prophylaxis for variceal bleeding: carvedilol vs. propranolol.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Drug Monitoring; Esophageal and | 2017 |
Early identification of haemodynamic response to pharmacotherapy is essential for primary prophylaxis of variceal bleeding in patients with 'high-risk' varices.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Esophageal and Gastric Varices; Female; | 2009 |
Propranolol reduces variceal pressure and wall tension in schistosomiasis presinusoidal portal hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Animals; Endosonography; Esophageal and Gastric Varices; Esophag | 2009 |
Oral propranolol decreases intestinal permeability in patients with cirrhosis: another protective mechanism against bleeding?
Topics: Adrenergic beta-Antagonists; Bacterial Translocation; Clinical Trials as Topic; Esophageal and Gastr | 2009 |
A specialized, nurse-run titration clinic: a feasible option for optimizing beta-blockade in non-clinical trial patients.
Topics: Adrenergic beta-Antagonists; Ambulatory Care Facilities; Esophageal and Gastric Varices; Female; Gas | 2010 |
[Beta-blockers in portal hypertension: Unexpected limitations!].
Topics: Adrenergic beta-Antagonists; Cause of Death; Esophageal and Gastric Varices; Esophagoscopy; Gastroin | 2011 |
Effects of beta-blockers on survival for patients with cirrhosis and refractory ascites.
Topics: Adrenergic beta-Antagonists; Ascites; Contraindications; Esophageal and Gastric Varices; Gastrointes | 2011 |
Evening administration of long-acting beta-blockers for primary prophylaxis in cirrhosis: an effective strategy.
Topics: Adrenergic beta-Antagonists; Delayed-Action Preparations; Drug Administration Schedule; Esophageal a | 2011 |
Non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Elasticity; Elasticity Imaging Technique | 2012 |
Successful pregnancy in a woman with liver cirrhosis complicated by recurrent variceal bleeding.
Topics: Adult; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Gestational Age; Humans; | 2012 |
Rectal bleeding and hypertensive colopathy in May-Thurner syndrome.
Topics: Adolescent; Colon; Colonic Diseases; Colonic Diseases, Functional; Delayed Diagnosis; Diagnosis, Dif | 2013 |
Pharmacologic efficacy in gastric variceal rebleeding and survival: including multivariate analysis.
Topics: Adrenergic beta-Antagonists; Carcinoma, Hepatocellular; Esophageal and Gastric Varices; Female; Gast | 2002 |
"A la carte" treatment of portal hypertension or just "hors d'oeuvres".
Topics: Gastrointestinal Hemorrhage; Hemodynamics; Humans; Hypertension, Portal; Isosorbide Dinitrate; Losar | 2003 |
Optimal use of propranolol.
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Isosorbide Dinitrate; Ligation; | 2003 |
Long-term outcome after sclerotherapy with or without a beta-blocker for variceal bleeding in children.
Topics: Antihypertensive Agents; Child; Child, Preschool; Combined Modality Therapy; Esophageal and Gastric | 2003 |
Ectopic intestinal varices as a rare cause of lower gastrointestinal haemorrhage.
Topics: Antihypertensive Agents; Endoscopy, Digestive System; Esophageal and Gastric Varices; Gastrointestin | 2003 |
Management of cirrhosis and ascites.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Esophageal and Gastric Varices; Gastrointest | 2004 |
[Variceal hemorrhage: primary and secondary prophylaxis].
Topics: Adrenergic beta-Antagonists; Algorithms; Esophageal and Gastric Varices; Esophagoscopy; Gastrointest | 2004 |
Treatment of recurrent gastrointestinal haemorrhage in a patient with von Willebrand's disease with octreotide LAR and propranolol.
Topics: Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Octreotide; Propr | 2005 |
Can somatostatin control acute bleeding from oesophageal varices in Schistosoma mansoni patients?[ISRCTN63456799].
Topics: Adolescent; Anthelmintics; Antihypertensive Agents; Child; Drug Therapy, Combination; Esophageal and | 2004 |
Epinephrine protects against severe acute gastric bleeding in rats: role of nitric oxide and glutathione.
Topics: Adrenergic alpha-Agonists; Animals; Blood Pressure; Enzyme Inhibitors; Epinephrine; Gastric Mucosa; | 2005 |
Primary prophylaxis against variceal bleeding: beta-blockers, endoscopic ligation, or both?
Topics: Adrenergic beta-Antagonists; Combined Modality Therapy; Esophageal and Gastric Varices; Esophagoscop | 2005 |
[Hemodynamic response to a single dose of intravenous propranolol in the prophylaxis of variceal bleeding].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Pressure; Drug Evaluation; Esophageal and G | 2005 |
Is banding ligation for primary prevention of variceal bleeding as effective as beta-blockers, and is it safe?
Topics: Adrenergic beta-Antagonists; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Li | 2006 |
[Hemorrhage due to peristomal ectopic varices: an infrequent complication of portal hypertension].
Topics: Cecal Neoplasms; Colonic Neoplasms; Diabetes Mellitus, Type 2; Duodenal Ulcer; Gastrointestinal Hemo | 2006 |
Chronic stomal variceal bleeding after colonic surgery in patients with portal hypertension: efficacy of beta-blocking agents?
Topics: Adrenergic beta-Antagonists; Aged; Chronic Disease; Colostomy; Gastrointestinal Hemorrhage; Humans; | 2006 |
A patient with diabetes mellitus and recurrent peristomal bleeding.
Topics: Aged; Antihypertensive Agents; Colostomy; Diabetes Mellitus, Type 2; Diagnosis, Differential; Electr | 2006 |
[Prevention of variceal bleeding and measurement of hepatic vein pressure gradient].
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Esophageal and Gastric Varices; Gastrointest | 2006 |
The low incidence of bacterial infections could be a protective factor against variceal bleeding per se in hemodynamic responders to propranolol.
Topics: Antihypertensive Agents; Bacterial Infections; Esophageal and Gastric Varices; Gastrointestinal Hemo | 2006 |
Clinical trials for variceal bleeding: and the winner is--the patient.
Topics: Adrenergic beta-Antagonists; Clinical Trials as Topic; Gastrointestinal Hemorrhage; Humans; Liver Tr | 2007 |
How to prevent varices from bleeding: shades of grey--the case for nonselective beta blockers.
Topics: Adrenergic beta-Antagonists; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hemodynami | 2007 |
Management practices for gastrointestinal hemorrhage related to portal hypertension in cirrhotic patients: evaluation of the impact of the Paris consensus workshop.
Topics: Adrenergic beta-Antagonists; Antibiotic Prophylaxis; Drug Utilization; France; Gastrointestinal Hemo | 2007 |
[Therapy of bleeding esophageal varices].
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Propranolol; Somatostatin; Vaso | 1982 |
Drug therapy of portal hypertension due to cirrhosis.
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hemodynamics; Humans; Hypertension, Por | 1982 |
[Beta-blockers and portal hypertension].
Topics: Adrenergic beta-Antagonists; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Liver Cirrho | 1984 |
Drug therapy of portal hypertension and oesophageal varices.
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Propranol | 1984 |
[Criticism of drug therapy of gastrointestinal hemorrhage].
Topics: Cimetidine; Gastrointestinal Hemorrhage; Humans; Propranolol; Somatostatin; Vasopressins | 1984 |
Recurrent bleeding and propranolol?
Topics: Carcinoma, Hepatocellular; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Live | 1983 |
[Therapy of bleeding esophageal varices].
Topics: Embolization, Therapeutic; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Port | 1984 |
Precipitation of hepatic encephalopathy by propranolol in cirrhosis.
Topics: Aged; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; H | 1983 |
Propranolol does not further decrease the clearance of antipyrine in patients with alcoholic cirrhosis.
Topics: Adult; Antipyrine; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis, Alcoholic; Male; Metabolic | 1983 |
Propranolol withdrawal and variceal hemorrhage.
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hypertension; Male; Middle Aged | 1983 |
Effect of propranolol and sclerotherapy in bleeding esophageal varices. A case report.
Topics: Combined Modality Therapy; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Huma | 1984 |
Sclerosing peritonitis and propranolol.
Topics: Angina Pectoris; Colon; Gastrointestinal Hemorrhage; Humans; Hypertension; Male; Middle Aged; Perito | 1981 |
[Propranolol treatment of hemorrhage due to portal hypertension].
Topics: Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Propranolol | 1981 |
Propranolol in gastrointestinal bleeding from cirrhosis.
Topics: Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Propranolol | 1982 |
[Medical treatment of hemorrhage in portal hypertension of the cirrhotic patient using propanolol].
Topics: Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Liver Cirrhosis; Propranolol; Recurrence | 1982 |
Injection sclerotherapy of esophageal varices.
Topics: Endoscopy; Esophageal and Gastric Varices; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; L | 1982 |
Propranolol for gastrointestinal bleeding in cirrhosis.
Topics: Administration, Oral; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cir | 1982 |
[Endoscopic sclerotherapy: does propranolol reduce the risk of hemorrhagic recurrence?].
Topics: Combined Modality Therapy; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Live | 1994 |
[Per-rectal scintigraphy of the portal system with pertechnetate TC-99M: effect of propranolol on portosystemic collateral circulation in patients with cirrhosis. Part II].
Topics: Adult; Aged; Blood Pressure; Collateral Circulation; Esophageal and Gastric Varices; Female; Gastroi | 1994 |
[Current therapeutic possibilities in esophageal varices].
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hemostatics; Humans; Propranolol; Scler | 1994 |
Sclerotherapy versus propranolol after a variceal bleed.
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Propranolol; Prospective Studie | 1993 |
Bleeding varices due to portal hypertension in sarcoidosis. Favorable effect of propranolol and prednisone.
Topics: Drug Therapy, Combination; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hype | 1993 |
Effect of antihypertensive drugs on ethanol induced gastric lesions: is there a correlation with mucosal blood flow?
Topics: Animals; Antihypertensive Agents; Blood Pressure; Drug Interactions; Ethanol; Gastric Mucosa; Gastro | 1993 |
[Estrogens and propranolol in the treatment of chronic iron-deficiency anemia due to gastric vascular malformations].
Topics: Anemia, Hypochromic; Arteriovenous Malformations; Chronic Disease; Drug Therapy, Combination; Estrad | 1993 |
Propranolol in the control of haemorrhage from varices around a urostomy.
Topics: Aged; Anastomosis, Surgical; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hy | 1993 |
Portal hypertension revisited.
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Portasyst | 1995 |
Long-term treatment of bleeding caused by portal hypertension in children.
Topics: Administration, Oral; Adult; Child; Esophageal and Gastric Varices; Esophagoscopy; Gastrointestinal | 1997 |
Primary prevention of bleeding from esophageal varices.
Topics: Adrenergic beta-Antagonists; Endoscopy; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; | 1999 |
Propranolol and portal hypertension: should kids be on the block?
Topics: Antihypertensive Agents; Child; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; | 1999 |
Prevention of a first episode of variceal bleeding: role of duplex Doppler sonographic measurement of the acute response to beta-blockers.
Topics: Actuarial Analysis; Adrenergic beta-Antagonists; Blood Flow Velocity; Esophageal and Gastric Varices | 1999 |
Therapeutic face-off: band ligation versus beta blockage for variceal bleeding.
Topics: Adrenergic beta-Antagonists; Endoscopy; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; | 2000 |
Variceal bleeding prophylaxis: variceal banding or propranolol.
Topics: Adrenergic beta-Antagonists; Endoscopy; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; | 2000 |
Beta-blocker plus nitrate for primary prophylaxis of variceal bleeding.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Esophageal and Gastric Varices; Gastrointestinal Hemorr | 2000 |
The portal flow velocity test is predictive of effective prevention of variceal bleeding.
Topics: Adrenergic beta-Antagonists; Blood Flow Velocity; Esophageal and Gastric Varices; Forecasting; Gastr | 2001 |
Blind beta blockade.
Topics: Adrenergic beta-Antagonists; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hemodynami | 2001 |
Lebrec D, Poynard T, Hillon P, Benhamou J-P. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis. A controlled study [N Engl J Med 1981;305:1371-1374].
Topics: Gastrointestinal Hemorrhage; History, 20th Century; Humans; Liver Cirrhosis; Propranolol; Secondary | 2002 |
Traumatic hemobilia: a complication of percutaneous liver biopsy.
Topics: Adult; Alcoholism; Bile; Biliary Tract Diseases; Biopsy, Needle; Blood; Chemical and Drug Induced Li | 1977 |
Beta-blockers in prevention of variceal hemorrhage: tantalizing expectations.
Topics: Adrenergic beta-Antagonists; Confounding Factors, Epidemiologic; Esophageal and Gastric Varices; Gas | 1992 |
Propranolol for portal hypertensive gastropathy: another virtue of beta-blockade?
Topics: Adrenergic beta-Antagonists; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Liver Cirrho | 1992 |
Cessation of recurrent bleeding from gastrointestinal angiodysplasia, after beta blocker treatment in a patient with hypertrophic subaortic stenosis--a case history.
Topics: Aged; Angiodysplasia; Cardiomyopathy, Hypertrophic; Cecal Diseases; Combined Modality Therapy; Femal | 1992 |
Protective effect of propranolol on ethanol-induced gastric lesions in rats: probable mechanism of action.
Topics: Animals; Drug Interactions; Ethanol; Gastric Fundus; Gastrointestinal Hemorrhage; Indomethacin; Lido | 1992 |
[Adrenergic beta blockade in liver cirrhosis with portal hypertension? Doppler ultrasound measurement of the short-term effect of propranolol on the portal system].
Topics: Blood Flow Velocity; Esophageal and Gastric Varices; Follow-Up Studies; Gastrointestinal Hemorrhage; | 1992 |
Beta-blockers in portal hypertension: variation on a theme.
Topics: Acute Disease; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Propranolol | 1992 |
Hypovolaemia inhibits acid-induced alkaline transport in the rat duodenum via an alpha-2 adrenergic mechanism.
Topics: Animals; Bicarbonates; Biological Transport; Blood Pressure; Blood Volume; Duodenum; Gastrointestina | 1991 |
[Propranolol in portal hypertensive gastropathy].
Topics: Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Liver Cirrhosis; Propranolol; Stomach Dis | 1991 |
[Sclerosing treatment of esophageal varices].
Topics: Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; L | 1991 |
[Gastro-esophageal symptoms in cirrhosis].
Topics: Aged; Endoscopy, Gastrointestinal; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Huma | 1991 |
Treating esophageal varices prophylactically.
Topics: Esophageal and Gastric Varices; Esophagoscopy; Gastrointestinal Hemorrhage; Humans; Propranolol; Scl | 1991 |
Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage.
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Propranolol | 1991 |
Propranolol for prophylactic treatment of a first variceal hemorrhage.
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Propranolol | 1991 |
Variceal hemorrhage--to block or not to block?
Topics: Adrenergic beta-Antagonists; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Pr | 1990 |
Combination therapies may speed healing, reduce rebleeding of esophageal varices.
Topics: Combined Modality Therapy; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liga | 1991 |
Protective effect of propranolol on ethanol-induced gastric lesions in mice.
Topics: Administration, Oral; Animals; Ethanol; Gastrointestinal Hemorrhage; Indomethacin; Injections, Intra | 1990 |
Variceal bleeding and beta-blockade: permutation on the theme?
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Propranolol; Sclerotherapy | 1990 |
[Prevention of gastrointestinal hemorrhage caused by portal thrombosis with propranolol. Report of a case with an 8 year follow-up].
Topics: Aged; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Male; Portal Vei | 1990 |
Propranolol-induced reduction in recurrent variceal hemorrhage in schistosomiasis.
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Propranolol; Recurrence; Schist | 1990 |
Effect of propranolol on oesophageal variceal pressure in a patient with extrahepatic portal obstruction.
Topics: Blood Pressure; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Male; Middle Ag | 1989 |
Hyperkinetic circulatory syndrome in patients with presinusoidal portal hypertension. Effect of propranolol.
Topics: Adult; Collateral Circulation; Female; Gastrointestinal Hemorrhage; Heart Rate; Hemodynamics; Hepati | 1989 |
[The use of anaprilin for the correction of portal hypertension in liver cirrhosis].
Topics: Adult; Aged; Ascites; Drug Evaluation; Female; Gastrointestinal Hemorrhage; Hemodynamics; Humans; Hy | 1989 |
"Low T3 syndrome" in cirrhosis: effect of beta-blockade.
Topics: Adult; Aged; Ascites; Euthyroid Sick Syndromes; Female; Gastrointestinal Hemorrhage; Humans; Liver C | 1989 |
Preventing hemorrhage from esophageal varices.
Topics: Adrenergic beta-Antagonists; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Li | 1987 |
[Prevention of hemorrhagic recurrence in Child's group A cirrhotic patients].
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Portacaval Shu | 1987 |
[Prevention of hemorrhagic recurrence in cirrhotic patients. Is sclerotherapy better than propranolol?].
Topics: Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Male; | 1988 |
Propranolol and hemorrhage from esophageal varices.
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Propranolol | 1988 |
[Hemorrhage caused by portal hypertension at the level of a colostomy. Efficacy of propranolol?].
Topics: Colostomy; Female; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Middle Aged; Propranol | 1988 |
Persistent hemorrhagic gastritis in a patient with portal hypertension and esophagogastric varices: the role of portal decompressive surgery.
Topics: Aged; Esophageal and Gastric Varices; Female; Gastritis; Gastrointestinal Hemorrhage; Humans; Hypert | 1988 |
Bleeding colonic varices controlled by propranolol.
Topics: Colonic Diseases; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cirrhos | 1988 |
Does propranolol precipitate hepatic encephalopathy?
Topics: Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; Humans; | 1986 |
[Prevention of recurrent hemorrhage due to portal hypertension].
Topics: Double-Blind Method; Esophageal and Gastric Varices; Esophagoscopy; Gastrointestinal Hemorrhage; Hum | 1986 |
Reversal of adrenaline-induced increase in azygos blood flow in patients with cirrhosis receiving propranolol.
Topics: Adult; Azygos Vein; Drug Interactions; Epinephrine; Esophageal and Gastric Varices; Female; Gastroin | 1987 |
Emergency portacaval shunt for variceal hemorrhage. A prospective study.
Topics: Emergencies; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Middle Aged; Porta | 1987 |
Comparative study between propranolol and sclerotherapy in prophylactic treatment of oesophageal varices and prevention of recurrent bleeding attacks.
Topics: Adult; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Propr | 1987 |
Management of bleeding oesophageal varices.
Topics: Esophageal and Gastric Varices; Esophagoscopy; Gastrointestinal Hemorrhage; Hemostatic Techniques; H | 1986 |
[Resuscitation of hemorrhagic shock in cirrhotics taking propranolol].
Topics: Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Propranolol; Resuscitation; Shock, Hemorrhagic | 1985 |
[Indications for surgery in portal hypertension from the internist's viewpoint].
Topics: Ascites; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; | 1985 |
Superior portosystemic collateral circulation estimated by azygos blood flow in patients with cirrhosis. Lack of correlation with oesophageal varices and gastrointestinal bleeding. Effect of propranolol.
Topics: Azygos Vein; Collateral Circulation; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hu | 1985 |
[How many cirrhotic patients may receive propranolol after digestive hemorrhage?].
Topics: Adult; Aged; Female; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Male; Middle Aged; Propra | 1985 |
[Propranolol and hemorrhage in cirrhosis].
Topics: Adult; Aged; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Humans; Liver Cirr | 1985 |
[Propranolol prevention of hemorrhagic recurrence caused by rupture of esophageal varices: worsened prognosis in ascites and jaundice].
Topics: Ascites; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Humans; Jaundice; Live | 1985 |
Effects of adrenergic blocking agents on gastric secretion and stress-induced gastric ulcer in rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Depression, Chemical; Dibenzylch | 1970 |
[Participation of catecholamines in the development of corticosteroid lesions in the gastric mucous membrane].
Topics: Animals; Catecholamines; Gastric Mucosa; Gastrointestinal Hemorrhage; Male; Mitosis; Parasympatholyt | 1972 |
[Angiographic diagnosis and therapy of acute gastrointestinal hemorrhage].
Topics: Aged; Angiography; Epinephrine; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; | 1972 |
[Radiographic diagnosis and therapy of digestive tract hemorrhage].
Topics: Gastrointestinal Hemorrhage; Humans; Propranolol; Radiography; Vasopressins | 1973 |
Selective arterial infusion of vasoconstrictor medication in the treatment of gastrointestinal bleeding due to systemic Lupus erythematosus.
Topics: Adult; Epinephrine; Female; Gastrointestinal Hemorrhage; Humans; Injections, Intra-Arterial; Lupus E | 1973 |
Selective arterial drug infusions in the treatment of acute gastrointestinal bleeding. A preliminary report.
Topics: Acute Disease; Adult; Aged; Alcoholism; Animals; Colitis; Colitis, Ulcerative; Diverticulum, Colon; | 1970 |
Pharmacological control of upper gastrointestinal bleeding.
Topics: Angiography; Epinephrine; Gastrointestinal Hemorrhage; Humans; Propranolol; Vagotomy | 1971 |
Selective arterial infusions of vasoconstrictors in acute gastrointestinal bleeding.
Topics: Acute Disease; Adolescent; Adult; Aged; Angiography; Arteriosclerosis; Celiac Artery; Crohn Disease; | 1971 |
Gastrointestinal bleeding.
Topics: Animals; Blood Pressure; Cats; Dogs; Epinephrine; Gastrointestinal Hemorrhage; Humans; Intestines; P | 1971 |
[Radiographic control of acute gastrointestinal bleeding].
Topics: Acute Disease; Adolescent; Adult; Angiography; Animals; Blood Vessels; Catheterization; Celiac Arter | 1971 |